terazosin has been researched along with prazosin in 585 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 70 (11.97) | 18.7374 |
| 1990's | 216 (36.92) | 18.2507 |
| 2000's | 199 (34.02) | 29.6817 |
| 2010's | 79 (13.50) | 24.3611 |
| 2020's | 21 (3.59) | 2.80 |
| Authors | Studies |
|---|---|
| Bondinell, WE; Hieble, JP; Ruffolo, RR | 1 |
| Borden, LA; Branchek, TA; Forray, C; Gluchowski, C; Miao, SW; Wetzel, JM | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Arredondo, NF; Bantle, GW; Blue, DR; Clarke, DE; DeSousa, A; Elworthy, TR; Ford, AP; Gross, LM; Kava, MS; Lesnick, JD; Morgans, DJ; Ozer, RS; Palmer, WS; Pfister, JR; Repke, DB; Romero, M; Sandoval, L; Sjogren, EB; Talamás, FX; Vazquez, A; Vimont, RL; Williams, TJ; Wu, H; Zhu, QM | 1 |
| Bock, MG; Broten, TP; Chang, RS; DiSalvo, J; Forray, C; Patane, MA; Ransom, RW; Scott, AL | 1 |
| Bendesky, R; Broten, TP; Chang, RS; Chen, TB; Chiu, G; Forray, C; Harrell, CM; Lagu, B; Marzabadi, MR; Miao, SW; Murali Dhar, TG; Nagarathnam, D; O'Malley, S; Ransom, R; Schneck, K; Schorn, TW; Shen, Q; Sun, W; Tian, D; Tyagarajan, S; Vyas, KP; Wetzel, JM; Wong, WC; Zhang, F; Zhang, J | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Pedretti, A; Testa, B; Villa, L; Vistoli, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Kinsella, GK; Rodriguez, F; Rozas, I; Watson, GW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Al-Damluji, S; da Silva, JF; Ganellin, CR; Walters, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Chauhan, BS; Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bednarski, M; Dudek, M; Kulig, K; Lustyk, K; Malawska, B; Nowiński, L; Raźny, K; Sapa, J; Siwek, A; Starowicz, G; Zaręba, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bansal, R; Malhotra, A | 1 |
| Auerbach, S; Leifer, G; Lepor, H; Lowe, F; Madsen, P; Moon, T; Narayan, P; Puras-Baez, A; Soloway, M | 1 |
| Hartanto, V; Lepor, H; Shapiro, E | 1 |
| Fabricius, PG; Hannaford, JM | 1 |
| Buckley, JF; Chilton, CP; Ibrahim, I; Kaisary, AV; Kirk, D; Lloyd, SN | 1 |
| Laddu, A; Lepor, H | 1 |
| Di Silverio, F | 1 |
| Heinzl, S | 1 |
| Cleland, J; Coles, SJ; Humphreys, J; Ligueros, M; Unwin, R; Wilkins, MR | 1 |
| Horn, PT; Kohli, JD | 1 |
| Frohlich, ED; Nishikimi, T; Uchino, K | 2 |
| Kyncl, JJ; Lepor, H; Meretyk, S; Shapiro, E; Tang, R | 1 |
| Black, HR; Chrysant, SG; Curry, CL; Frishman, WH; Grimm, RH; Lasseter, KC; Okun, R; Pool, JL; Raizada, V; Vlachakis, ND | 1 |
| Frewin, DB; Head, RJ; Jonsson, JR | 1 |
| Guy, S; Humphreys, JE; Silke, B | 1 |
| Achari, R; Laddu, A | 1 |
| Blaschke, TF; Dachman, W; Hoffman, BB; Vincent, J | 1 |
| Angeli, M; Azar, E; Bueno, O; Lema, G; Morales, N; Nuchi, Y; Rasines, C; Romero, E; Velasco, M; Wagner, A | 1 |
| Lepor, H; Machi, G | 1 |
| Kondo, S; Morita, T | 1 |
| Knapp-Maloney, G; Lepor, H; Meretyk, S | 1 |
| Laddu, A; Matzkin, H; Rangel, MC; Soloway, MS | 1 |
| Arai, Y; Hayashida, H; Inoue, H; Kataoka, K; Kitagawa, Y; Kurita, T; Nagai, N; Nishioka, T; Park, YC; Tomoyoshi, T | 1 |
| Woods, AL | 1 |
| Harada, T; Nishizawa, O; Noto, H; Otomo, R; Satoh, K; Shimoda, N; Sugaya, K; Takahashi, T; Tsuchida, S | 1 |
| Hosmane, BS; Jordan, DC; Laddu, A; Maurath, CJ | 1 |
| Coles, S; Lytle, T; Waite, MA | 1 |
| Kaplan, NM; Khoury, AF | 1 |
| Carlson, K; Frishman, W; Jordan, A; Laddu, A; Strom, JA; Wexler, JP; Zola, B | 1 |
| Achari, R; Laddu, AR; Somberg, JC | 1 |
| Cheung, DG; Laddu, AR; Luther, RR; Weber, MA | 1 |
| Grimm, RH | 2 |
| Cohen, JD | 1 |
| Pool, JL | 1 |
| Saunders, E | 1 |
| Coles, SJ; Lytle, TB; Waite, MA | 1 |
| Anthone, GJ; Orandle, MS; Wang, BH; Yeo, CJ | 1 |
| Conway, EL; Drummer, OH; Louis, WJ; McNeil, JJ; Raymond, K | 1 |
| Kinami, J; Maruyama, K; Nagatomo, T; Tsuchihashi, H | 1 |
| Lepor, H | 3 |
| Dunzendorfer, U; Fabricius, PG; Hannaford, JM; Maurath, C; Weizert, P | 1 |
| Knapp-Maloney, G; Lepor, H; Sunshine, H | 1 |
| Henry, D; Laddu, AR; Lepor, H | 1 |
| Ferrari, P; Neuner, N; Riesen, W; Rosman, J; Shaw, S; Weidmann, P | 1 |
| Morita, T | 1 |
| Boudoulas, H; Leier, CV; Magorien, RD; Sinnathamby, S; Unverferth, DV | 1 |
| Achari, R; Glassman, HN; Klepper, MJ; Laddu, AR; Luther, RR; Maurath, CJ | 2 |
| Mikawa, M; Sasayama, S; Takata, M; Tomoda, F; Yasumoto, K; Yoshida, K | 2 |
| Horn, PT; Kohli, JD; Mercuro, G; Orelind, ER | 1 |
| Liu, G | 1 |
| Kagiya, T; Karliner, JS; Simpson, PC | 1 |
| Conway, EL; Drummer, OH; Louis, WJ; McNeil, JJ; Workman, BS | 1 |
| Iida, H; Ikeda, K; Mikawa, M; Sasayama, S; Takata, M; Tomoda, F | 1 |
| Anavekar, SN; Conway, EL; Drummer, OH; Howes, LG; Jarrott, B; Louis, WJ; McNeil, JJ; Workman, B | 1 |
| Baumann, M; Lepor, H; Shapiro, E | 1 |
| Baumann, M; Gup, DI; Lepor, H; Shapiro, E | 1 |
| Dunzendorfer, U | 2 |
| Knapp-Maloney, G; Lepor, H; Wozniak-Petrofsky, J | 1 |
| Estep, CB; Glassman, HN; Jordan, DC; Luther, RR; Maurath, CJ | 1 |
| Nagatomo, T; Tsuchihashi, H | 1 |
| Luther, RR | 1 |
| Abadir, AR; Alver, JE; Gintautas, J; Kester, RR; Kim, H; Mooppan, UM | 1 |
| Rosenthal, J | 2 |
| Abe, Y; Fukui, K; Iwao, H; Shoji, T; Tamaki, T | 1 |
| Bishopric, NH; Ordahl, CP; Simpson, PC | 1 |
| Bal, IS; Chrysant, SG; Johnson, B; McPherson, MA | 1 |
| Beretta-Piccoli, C; Ferrier, C; Weidmann, P | 2 |
| Kyncl, JJ | 2 |
| Sonders, RC | 1 |
| Glassman, HN; Luther, RR; Sperzel, WD | 1 |
| Dauer, AD | 1 |
| Ruoff, G | 2 |
| Rudd, P | 1 |
| Chrysant, SG | 1 |
| Deger, G | 2 |
| Mersey, JH | 1 |
| Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD | 2 |
| Cohen, A | 1 |
| Chauveau, P; Ganeval, D; Jungers, P; Pertuiset, N | 1 |
| Bhamra, RK; Flanagan, RJ; Holt, DW | 1 |
| Huss, P; Leier, CV; Parrish, D; Patterson, SE; Unverferth, DV | 1 |
| Beretta-Piccoli, C; Ferrier, C; Mordasini, R; Weidmann, P | 1 |
| Hanazuka, M; Horii, D; Mizogami, S | 1 |
| Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Sperzel, WD; Steinberg, FJ | 1 |
| Hasegawa, T; Takahashi, K | 1 |
| Itoh, H; Kohli, JD; Rajfer, SI | 1 |
| Hayduk, K | 1 |
| Hayduk, K; Schneider, HT | 1 |
| Monk, JP; Titmarsh, S | 1 |
| Hanazuka, M; Nishi, H; Watanabe, T; Yuki, S | 1 |
| Aono, J; Hokibara, R; Nagatomo, T; Nakamura, T; Tajiri, A; Tanaka, Y; Tsuchihashi, H | 1 |
| Alibali, P; Bump, T; Carroll, JD; Coggins, DL; Feldman, M; Feldman, T; Gray, KR; Munkenbeck, F | 1 |
| Eisen, G; Frishman, WH; Lapsker, J | 1 |
| Rodman, MJ | 1 |
| Harvengt, C | 1 |
| Bessho, H; Hara, Y; Horii, D; Kimura, Y; Narimatsu, A; Tobe, A | 1 |
| Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ | 1 |
| Mitchell, JR; Nelson, EB; Pool, JL; Taylor, AA | 1 |
| Henrich, CJ; Simpson, PC | 1 |
| Glassman, HN; Jordan, DC; Luther, RR; Sennello, LT; Sonders, RC; Tolman, KG | 1 |
| Simpson, P | 1 |
| Hussar, DA | 1 |
| Holtzman, JL; Kaihlanen, PM; Lewin, AJ; Oberlin, JA; Rider, JA; Spindler, JS | 1 |
| Carroll, JD; Itoh, H; Lang, RM; Nakamura, S; Rajfer, SI | 1 |
| Patterson, SE | 2 |
| Frisk-Holmberg, M | 1 |
| Cusick, PK; Fort, FL; Heyman, IA; Kesterson, JW; Majors, K; Tekeli, S | 1 |
| Brewer, DD; DeYoung, JL; Drayer, JI; Weber, MA | 1 |
| Oates, HF | 1 |
| Konen, JC | 1 |
| Adams, G; Brawer, MK; Epstein, H | 1 |
| Moon, TD; Neal, DE | 1 |
| Bottaccini, MR; Gleason, DM | 1 |
| Caine, M | 1 |
| Lowe, FC | 1 |
| Guthrie, R | 1 |
| Ferretti, S; Larosa, M; Salsi, P; Simonazzi, M | 1 |
| Jerant, AF | 1 |
| Stockamp, K | 1 |
| Geller, J; Kirchenbaum, A; Lepor, H; Levine, AC | 1 |
| Andres, M; Carmignani, L; De Cobelli, O; Kocjancic, E; Musci, R; Panizzutti, M; Rocco, F | 1 |
| Moon, L; Pfettscher, S | 1 |
| Bartek, JK; McNamee, M | 1 |
| Kreder, KJ | 1 |
| Chmiel, JJ; Hillman, AL; Lowe, FC; McDaniel, RL | 1 |
| de Groat, WC; Somogyi, GT; Tanowitz, M | 1 |
| Barry, MK; Gontarek, JD; Jimenez, RE; Maher, MM; Yeo, CJ | 1 |
| Breslin, D; Chou, TC; Felsen, D; Fields, DW; Kane, M; Marion, DN; Vaughan, ED | 1 |
| Ramsey, EW | 1 |
| Takahashi, T | 1 |
| Brawer, MK | 1 |
| Elliott, WJ | 1 |
| Johnston, W; Laddu, AR; Lenz, ML; Pool, JL; Taylor, AA; Varghese, A | 1 |
| Lepor, H; Theune, C | 1 |
| Chancellor, MB; Huang, B; Rivas, DA; Salzman, SK | 1 |
| Maruyama, K; Nagatomo, T; Ohkura, N; Yagi, Y | 1 |
| Kyncl, JJ; Rosenthal, J | 1 |
| Horky, K | 1 |
| Ram, CV | 1 |
| Hańczycowa, H; Jordanek, P; Jurga, M; Ponikowski, P; Rotter, A; Sebzda, T; Spring, A | 1 |
| Chancellor, MB; Erhard, MJ; Hirsch, IH; Stass, WE | 1 |
| Chancellor, MB; Erhard, MJ; Rivas, DA | 1 |
| Liu, Z; Lu, Z; Wang, D; Yang, D; Zhu, J | 1 |
| Belville, WD; Gormley, EA; McGuire, EJ; Sweetser, PM; Swierzewski, SJ; Wan, J | 1 |
| Gotoh, E; Hata, T; Ikegami, H; Ito, T; Iwatsubo, H; Mikami, H; Ogihara, T; Otsuka, A; Shionoiri, H; Takegawa, K | 1 |
| Wang, W | 1 |
| Arrostuto, A; Correo, S; Ingurgio, NC; Licata, G; Martino, S; Paterna, S | 1 |
| Carter, AJ; Greengrass, PM; Kenny, BA; Naylor, AM; Read, AM; Wyllie, MG | 1 |
| De Toni, R; Fazari, G; Fontebasso, A; Gebbin, A; Pessina, AC; Semplicini, A; Serena, L; Valle, R | 1 |
| De Toni, R; Fontebasso, A; Gebbin, A; Gerardi, G; Pessina, AC; Semplicini, A; Serena, L; Valle, R | 1 |
| Barry, MK; Gontarek, JD; Pickering, SP; Yeo, CJ | 1 |
| Benavides, J; Claustre, Y; Rouquier, L | 1 |
| Cohen, J | 1 |
| Divish, B; Langenstroer, P; Lepor, H; Opgenorth, T; Shapiro, E; Tang, R | 1 |
| Campia, U; Cardillo, C; De Felice, F; Degen, C; Folli, G | 1 |
| Frohlich, ED; Komatsu, K; Numabe, A | 1 |
| Cheng, L | 1 |
| Cavallini, G | 1 |
| Kaplan, SA; Olsson, CA; Soldo, KA | 1 |
| Scheen, AJ | 1 |
| Drescher, P; Knes, JM; Madsen, PO; Rauch, D | 1 |
| Frankel, G | 1 |
| Perkash, I | 1 |
| Auerbach, S; Kaplan, SA; Lloyd, LK; Milam, DE; Oesterling, JE; Padley, RJ; Roehrborn, CG | 1 |
| Deverka, PA; Hillman, AL; Mason, MF; Maurath, CJ; Oesterling, JE; Padley, RJ; Peskin, E; Roehrborn, CG; Schwartz, JS; Willian, MK | 1 |
| Lee, JH; McCarty, R | 1 |
| de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP | 1 |
| Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J | 1 |
| Chapple, CR | 2 |
| Walsh, PC | 1 |
| Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO | 1 |
| Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R | 1 |
| Ramage, AG; Wyllie, MG | 1 |
| Miranda, HF; Naquira, D; Pinardi, G; Sierralta, F | 1 |
| Beevers, DG; Marshall, HJ | 1 |
| Abrahams, TP; Liu, W; Varner, KJ | 1 |
| Debruyne, FM; Fitzpatrick, J; Kirby, R; Kirk, D; Prezioso, D; Witjes, WP | 1 |
| Alonso-Galicia, M; Brands, MW; Hall, JE; Zappe, DH | 1 |
| Zacks, M | 1 |
| DuBeau, CE; Kuchel, GA; Resnick, NM | 1 |
| Lenders, JW; Thien, T | 1 |
| Cavanaugh, J; Eason, C; Granneman, GR; Hosmane, B; Locke, C; Samara, EE | 1 |
| Frankel, S | 1 |
| Brune, ME; Buckner, SA; Hancock, AA; Ireland, LM; Katwala, SP; Kerwin, JF; Milicic, I | 1 |
| Caris, CT; de la Rosette, JJ; Debruyne, FM; Rosier, PF; Witjes, WP | 1 |
| Eri, LM; Tveter, KJ | 1 |
| Vatz, KA | 1 |
| Andersson, KE; Lepor, H; Wyllie, MG | 1 |
| Dixon, C; Feser, J; Lepor, H; Nieder, A; O'Connell, C | 1 |
| Lowe, FC; McKiernan, JM | 1 |
| Bianco, G; Carella, M; Cera, A; Scarale, MG; Sperandeo, G; Sperandeo, M; Viola, M | 1 |
| Bishopric, NH; Pratt, RE; Wu, CF | 1 |
| Furuya, S; Isomura, H; Mikuma, N; Sawada, N; Tsukamoto, T; Yabu, H | 1 |
| Drabick, JJ; Gambel, JM; Mackey, JF | 1 |
| Cain, JC; Hancock, AA; Ireland, LM; Kerwin, JF; Rotert, G; Shoghi, S; Thomas, S | 1 |
| Evans, MF; Frank, J | 1 |
| de la Rosette, JJ; Debruyne, FM; Neal, DE; Robertson, A; Rosier, PF; Witjes, WP | 1 |
| Becopoulos, T; Christofis, I; Mitropoulos, D | 1 |
| Karien, RG; Maisel, RH | 1 |
| Brune, ME; Hancock, AA; Katwala, SP; Kerwin, JF; Milicic, I; Witte, DG | 1 |
| Gomi, T; Ikeda, T; Ikegami, F | 1 |
| Harmsen, E; Leenen, FH; Song, D | 1 |
| Arrostuto, A; Cannavò, MG; Cottone, C; Di Pasquale, P; Licata, G; Paterna, S; Pinto, A | 1 |
| Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
| Cabell, KS; Johnson, P; Ma, L | 1 |
| Chiba, T; Fukutomi, J; Hattori, K; Maruyama, K; Nagatomo, T; Takeda, M; Yamaguchi, M | 1 |
| Oesterling, JE; Olson, PJ; Padley, RJ; Roehrborn, CG | 1 |
| Buttrick, PM; Geenen, DL; Malhotra, A; Scheuer, J | 1 |
| Lee, C; Lee, E | 1 |
| Altenbach, RJ; Basha, FZ; Brune, ME; Buckner, SA; Carroll, WA; Drizin, I; Ehrlich, PP; Elmore, SW; Hancock, AA; Kerwin, JF; Lebold, SA; Meyer, MD; Plagge, F; Plata, DJ; Sippy, KB; Tietje, K; Wendt, MD | 1 |
| Trinkler, FB | 1 |
| Hattori, T; Ito, H; Sakakibara, R; Tojo, M; Yamanishi, T; Yasuda, K | 1 |
| Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL | 1 |
| Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE | 1 |
| Michel, MC; Schäfers, RF; Taguchi, K | 1 |
| Alebic-Kolbah, T; Zavitsanos, AP | 1 |
| Gordon, ES; Koman, LA; Li, Z; Smith, BP; Smith, TL | 1 |
| Michel, MC; Schäfers, RF | 1 |
| Suzuki, H | 1 |
| Beduschi, MC; Beduschi, R; Oesterling, JE | 1 |
| Koman, LA; Li, Z; Pollock, DC; Rosencrance, E; Smith, BP; Smith, TL; Strandhoy, JW | 1 |
| de Mey, C; McEwen, J; Michel, MC; Moreland, T | 1 |
| Achari, R; Baroldi, P; Cavanaugh, J; Cohen, A; Hosmane, B; Linnen, P | 1 |
| Bayne, ML; Burns, HD; Chang, RS; Chen, TB; DiSalvo, J; Francis, BE; Gibson, RE; Gluchowski, C; Marzabadi, M; Nagarathnam, D; O'Malley, SS; Wetzel, JM | 1 |
| Casado, M; Hernández-Cano, N; Herranz, P; Lázaro, TE; Mayor, M | 1 |
| Kumar, TV; Kumar, VP; Naidu, MU; Rani, PU; Rao, TR; Sekhar, EC; Sekhar, KR; Shobha, JC | 1 |
| Benos, DJ; Bradford, AL; Bubien, JK; Cornwell, T; DuVall, MD; Fuller, CM | 1 |
| Barry, MJ; Haakenson, C; Jones, K; Lepor, H; Williford, WO | 1 |
| Abe, I; Fujishima, M; Hasuo, Y; Nishino, Y; Onaka, U; Setoguchi, M | 1 |
| Kirby, RS | 1 |
| Chung, M; Hilbert, J; Lawrence, V; Phillips, K; Vashi, V | 1 |
| Bingley, J; Oo, T; Sett, P; Soni, BM; Vaidyanathan, S; Watt, JW | 1 |
| Krishnan, KR; Sett, P; Singh, G; Soni, BM; Vaidyanathan, S | 1 |
| Deguchi, Y; Higuchi, S; Honda, K; Inagaki, O; Kimura, R; Matsushima, H; Ohkura, T; Takenaka, T; Yamada, S | 1 |
| Muramatsu, I; Okada, K; Taniguchi, T | 1 |
| Bergman, JM; Broten, TP; Chang, RS; Chen, TB; Erb, JM; Guare, JP; Huff, JR; Lee, HY; Munson, PM; Nerenberg, JB; O'Malley, S; Schorn, TW; Scott, AL; Thompson, WJ | 1 |
| Djavan, B; Ghawidel, K; Marberger, M; Roehrborn, CG; Shariat, S | 1 |
| de Mey, C; Fokuhl, B; Michel, MC; Philipp, T; Schäfers, RF; Schumacher, H; Taguchi, K; Wasmuth, A | 1 |
| Goa, KL; Plosker, GL | 1 |
| Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW | 1 |
| Brawer, MK; Jones, K; Lepor, H; Lin, DW; Williford, WO | 1 |
| Djavan, B; Marberger, M | 1 |
| Liu, Z; Xu, S | 1 |
| Lowe, FC; Olson, PJ; Padley, RJ | 1 |
| Alvarez, C; Harris, SI | 1 |
| Hieble, JP; McCafferty, GP; Naselsky, DP | 1 |
| Albertsen, PC; Girman, CJ; Lowe, FC; Pellissier, JM; Roehrborn, CG | 1 |
| Fujimura, A; Harada, K; Kitoh, Y; Ohmori, M; Sugimoto, K | 1 |
| Gu, FL; Guo, YL; Na, YJ | 1 |
| Fuks, Z; Ginor, RX; Leibel, SA; Zelefsky, MJ | 1 |
| Lee, TH | 1 |
| Gogoi, S; Kumar, A; Mandhani, A; Srivastava, A | 1 |
| Quartermain, D; Rosengarten, H; Stone, EA; Yeretsian, J; Zhang, Y | 1 |
| Kageyama, S; Tamaki, M; Ueda, T | 1 |
| Hattori, T; Sakakibara, R; Tojo, M; Yamanishi, T; Yasuda, K | 1 |
| Alcini, E; Brisinda, G; Candidi, MO; Destito, A; Lacquaniti, S; Servello, C; Weir, JM | 1 |
| Hoffman, RM; Jansen, DJ; Resch, ND | 1 |
| Ferrara, LA; Imperatore, G; Iovine, C; Pasanisi, F; Vaccaro, O | 1 |
| Jones, K; Lepor, H; Williford, W | 1 |
| Kara, M; Krishnan, TR; Sharma, A; Smith, FR | 2 |
| Cerrato, PL | 1 |
| Hirao, Y; Kamidono, S; Kishimoto, T; Kurita, T; Okada, H; Okajima, E; Okuyama, A; Ozono, S; Park, Y; Yamamoto, K; Yoshioka, T | 1 |
| Antic, V; Kiener-Belforti, F; Montani, JP; Tempini, A; Van Vliet, BN | 1 |
| Tsujii, T | 1 |
| Fourcade, RO | 1 |
| Boumendil, O; Reitz, C; Rossi, D; Serment, G | 1 |
| Clifford, GM; Farmer, RD | 1 |
| Benning, CM; Kyprianou, N | 2 |
| Beckey, NP; Colon, A; Parra, D | 1 |
| Achari, R; Bonacci, E; Hosmane, B; O'Dea, R | 1 |
| Cheah, PY; Liong, ML; Yuen, KH | 1 |
| Bartsch, G | 1 |
| Bayne, CW; Habib, FK; Ross, M | 1 |
| Benning, CM; Chon, J; Kyprianou, N | 1 |
| Fitzpatrick, J | 1 |
| Caprino, L | 1 |
| de la ROSETTE, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS; Wijkstra, H | 1 |
| Gomi, T; Ikeda, T; Nagao, R; Shibuya, Y | 1 |
| Blanchard, K; Hananel, A; Rutchik, S; Sullivan, J | 1 |
| Archer, CL; Bennett, JK; El-Leithy, TR; Foote, J; Gray, M; Green, B; Saleem, MD | 1 |
| Basharkhah, A; Djavan, B; Fakhari, M; Harik, M; Marberger, M; Planz, B; Remzi, M; Roehrborn, CG; Seitz, C; Waldert, M | 1 |
| Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N | 1 |
| Mueller, J; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Wenning, GK | 1 |
| Cotecchia, S; Goepel, M; Hein, P; Michel, MC | 1 |
| Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y | 1 |
| Alkibay, T; Ataoglu , O; Atilla, S; Isen, K; Isik, S; Sezer, C; Sinik, Z; Sözen, S | 1 |
| Ikemoto, I; Ohishi, Y; Ohnishi, T; Suzuki, H; Suzuki, Y; Yamazaki, H | 1 |
| Akimoto, M; Horiuchi, K; Suzuki, Y; Tsuboi, N; Yoshida, K | 1 |
| De la Rosette, JJ; Farmer, RD; Herings, RM; Leufkens, HG; Man in 't Veld, AJ; Souverein, PC | 1 |
| Atwa, MA; Mahassini, SH; Mosli, HA | 1 |
| Altenbach, RJ; Bai, H; Basha, FZ; Brune, ME; Buckner, SA; Carroll, WA; Drizin, I; Hancock, AA; Kerwin, JF; Lebold, SA; Lee, E; Meyer, MD; Pratt, JK; Sippy, KB; Tietje, K; Wendt, MD | 1 |
| Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H | 1 |
| Agnello, G; Amadesi, S; Borea, PA; Daniele, C; Geppetti, P; Spisani, L; Turini, A; Varani, K; Zamboni, P | 1 |
| Lin, Y; Quartermain, D; Rosengarten, H; Stone, EA | 1 |
| Borkowski, A; Isaacs, JT; Jacobs, SC; Keledjian, K; Kim, G; Kyprianou, N | 1 |
| Akbay, E; Bozlu, M; Cayan, S; Doruk, E; Ulusoy, E | 1 |
| Eroğlu, M; Gül, O; Ozok, U | 1 |
| Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG | 1 |
| Akduman, B; Crawford, ED | 1 |
| Kaplan, SA | 1 |
| Gerth, J; Stolberg, SG | 1 |
| Brune, ME; Hancock, AA; Katwala, SP; Kerwin, JF; Meyer, MD; Milicic, I; Williams, M; Witte, DG | 1 |
| Brands, MW; Fitzgerald, SM | 1 |
| de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS | 1 |
| Andersson, KE; Gu, BJ; Igawa, Y; Ishizuka, O; Nishizawa, O | 1 |
| Boniecki, R; Jablonowski, Z; Kusnierz, J; Miekos, E; Rózanski, W; Trzepizur, Z; Zydek, C | 1 |
| Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T | 1 |
| Jacobs, SC; Kyprianou, N | 1 |
| Drummond, PD | 3 |
| Benevento, J; Horton, J; Linsenmeyer, TA | 1 |
| Cecchi, M; Di Benedetto, A; Summonti, D | 1 |
| Butler, WM; Galbreath, RW; Lief, JH; Merrick, GS; Wallner, KE | 1 |
| Drazba, J; Gaivin, R; Gonzalez-Cabrera, P; McCune, DF; Papay, R; Perez, DM; Ross, SA; Yun, J; Zuscik, MJ | 1 |
| Baykara, M; Ciftcioglu, MA; Emreoglu, I; Erdoğru, T; Gulkesen, KH; Koksal, T; Ozbilim, G; Usta, MF | 1 |
| Bur, A; Derhaschnig, U; Herkner, H; Hirschl, MM; Quehenberger, P; Woisetschläger, C | 1 |
| Li, J; Lu, R; Wang, J; Wang, JM | 1 |
| Alcaide, C; González-Juanatey, JR; Iglesias, MJ; Lago, F; Piñeiro, R | 1 |
| Howe, RW; MacDonald, R; Rutks, IR; Wilt, TJ | 1 |
| Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH | 2 |
| Chern, JW; Chou, JY; Guh, JH; Huang, YW; Pan, SL; Teng, CM | 1 |
| Brands, MW; Claxton, CR | 1 |
| Keledjian, K; Kyprianou, N | 1 |
| Niu, CQ; Ren, LM | 1 |
| Ahmed, A; Mudiyala, R | 1 |
| Fernández Salazar, L; Palencia García, A | 1 |
| Kyprianou, N | 1 |
| Ahsan, R; Grunewald, GL; Kramer, HK; Lin, Y; Quartermain, D; Rosengarten, H; Stone, EA | 1 |
| Issa, MM; Johnson, TM; Jones, K; Kutner, MH; Lepor, H; Williford, WO | 1 |
| Guarneri, L; Leonardi, A; Testa, R; Velasco, C | 1 |
| Gonzalez, CM; McVary, KT | 1 |
| Kang, BC; Rhee, JE; Shin, WG; Suh, OK; Yang, CQ | 1 |
| Cheng, L; Gong, P; Lu, Z; Tang, J; Zeng, F; Zhang, J | 1 |
| Romics, I | 1 |
| Fukabori, Y; Honma, S; Kashiwagi, B; Ono, Y; Shibata, Y; Suzuki, K; Yamanaka, H | 1 |
| Gakiya, M; Goya, M; Hatano, T; Ikehara, A; Kadekawa, K; Nakayama, T; Nashiro, F; Ogawa, Y; Sugaya, K | 1 |
| Ling, M; Wang, X; Wong, Y; Xu, K | 1 |
| Luo, JK; Sun, M; Zhang, WR | 1 |
| Lin, Y; Quartermain, D; Stone, EA | 1 |
| Bakshi, M; Ojha, T; Singh, S | 1 |
| Barber, D; Coffin-Beach, D; Pan, T; Sevick-Muraca, EM; Sun, Z | 1 |
| Adams, RC; Furness, MS; Gill, DS; Holcombe, FO; Raw, AS; Yu, LX | 1 |
| Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C | 1 |
| Kyprianou, N; Tahmatzopoulos, A | 1 |
| Brown, GA; Sussman, DO | 1 |
| Chen, HR; Deng, CH; Liu, JZ; Mei, H; Qiu, SP; Zheng, KL | 1 |
| Ficker, EK; Hammerling, BC; Karle, CA; Katus, HA; Kiehn, J; Kuryshev, YA; Schoels, W; Thomas, D; Wimmer, AB; Wu, K | 1 |
| Doggrell, SA | 1 |
| Kyprianou, N; Rowland, RG; Tahmatzopoulos, A | 1 |
| Fang, L; Lin, Q; Ren, Y; Wang, J; Willis, WD; Zou, X | 1 |
| Ahsan, R; Lin, Y; Quartermain, D; Stone, EA | 2 |
| Kirby, R | 1 |
| Hou, SK; Liu, SJ; Wang, XF; Wang, YC; Xu, KX | 1 |
| Brands, MW; Lee, DL; Webb, RC | 1 |
| Dincel, C; Samli, MM | 1 |
| Fang, L; Lin, Q; Ren, Y; Zou, X | 1 |
| Berntson, GG; Knox, D; Sarter, M | 1 |
| Ahuja, VM; Fahim, M; Sharma, R | 1 |
| Akbay, E; Bozlu, M; Cayan, S; Görür, S; Ulusoy, E | 1 |
| Braun, U; Poon, IO | 1 |
| Basar, H; Basar, MM; Batislam, E; Ferhat, M; Tuglu, D; Yilmaz, E | 1 |
| Conner, WT; Kyprianou, N; Lagrange, CA; Mitchell, BL; Tahmatzopoulos, A; Zeng, L | 1 |
| Ahsan, MR; Lin, Y; Quartermain, D; Stone, EA | 2 |
| Fahim, M; Pawar, A | 1 |
| Biswas, NR; Dogra, PN; Kumar, V; Mani, K; Ravi, AK | 1 |
| Carini, M; Lapini, A; Minervini, A; Serni, S | 1 |
| Fugit, RV; Glasheen, JJ; Prochazka, AV | 1 |
| Afshari, NA; Schwinn, DA | 1 |
| Başar, H; Başar, MM; Batislam, E; Ferhat, M; Yilmaz, E | 1 |
| Ahsan, MR; Lehmann, ML; Quartermain, D; Stone, EA; Yan, L; Yeretsian, J | 1 |
| Nagano, M; Osada, Y; Yamaguchi, T | 1 |
| Michel, MC; Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Someya, A; Suzuki, M; Ukai, M; Watanabe, M; Yanai-Inamura, H; Yuyama, H | 1 |
| Bauer, J; Dziki, W; Heitmann, W; Henry, R; Hollis, S; Leusen, FJ; Mannino, A; Morley, J; Quick, J; Spanton, S | 1 |
| de la Rosette, JJ; Michel, MC | 1 |
| O'Leary, MP | 1 |
| Kim, SW; Ku, JH; Paick, JS; Shin, JW; Yang, JH | 1 |
| Ku, JH; Lee, SC; Paick, JS | 1 |
| Ku, JH; Paick, JS; Shin, JW; Um, JM; Yang, JH | 1 |
| Alizadeh, F; Hosseini, SR; Mohseni, MG | 1 |
| Carr, KD; de Vaca, SC; Lin, Y; Stone, EA | 1 |
| Aletras, AJ; Hatzichristou, D; Kalinderis, N; Karakiulakis, G; Mitropoulos, D; Papakonstantinou, E; Zervas, A | 1 |
| Chan, E; Horner, RL; Liu, H; Steenland, HW | 1 |
| Burkhard, FC; Kessler, TM; Studer, UE | 1 |
| Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA | 1 |
| Jatwa, R; Kar, A | 1 |
| Bae, SK; Kwon, JW; Lee, DC; Lee, MG; Oh, EY; You, M | 1 |
| Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF | 1 |
| Jackson, I; Sadeghi-Nejad, H | 1 |
| Akova, YA; Altan-Yaycioglu, R; Ozkardes, H; Tufan, H; Yaycioglu, O | 1 |
| Carneiro, FS; Giachini, FR; Inscho, EW; Leite, R; Tostes, RC; Webb, RC | 1 |
| Chen, SZ; Chen, TF; Lin, QX; Lin, SG; Liu, XY; Peng, HY; Shan, ZX; Yang, M; Yu, XY; Zhou, SF; Zhou, ZL | 1 |
| Kagawa, Y; Kato, Y; Kawabe, K; Okura, T; Yamada, S | 1 |
| Ku, JH; Song, YS | 1 |
| Lan, SK; Ou, JH; Tsai, YS; Tzai, TS | 1 |
| Boone, TB; Hurtado, E; Smith, CP; Smith, PP; Somogyi, GT | 1 |
| Baron, AT; Becker, A; Conner, W; Durbin, EB; Harris, AM; Kimbler, K; Kyprianou, N; Lane, M; Rowland, RG; Warner, BW; Wilson, JM | 1 |
| Albo, G; Berardi, F; Colabufo, NA; Contino, M; de Rienzo, G; Niso, M; Pagliarulo, A; Pagliarulo, V; Perrone, R | 1 |
| Yang, MG; Zhao, XK | 1 |
| Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ | 1 |
| Collister, JP; Guzman, P; Osborn, JW | 1 |
| Koh, MJ; Mancer, K; Seah, PP; Tay, YK | 1 |
| Kitteringham, NR; Macdonald, I; Park, BK; Randle, LE; Sathish, JG; Williams, DP | 1 |
| Adayener, C; Akyol, I; Ates, F; Iseri, C; Senkul, T; Yilmaz, O | 1 |
| Lin, CC; Seak, CJ | 1 |
| Ku, JH; Kwak, C; Lee, JK | 1 |
| Buzuyeva, II; Filyushina, EE; Lazarev, VA; Markel', AL; Shmerling, MD; Yakobson, GS | 1 |
| Azanza, JR; Campanero, MA; Muñoz-Juarez, MJ; Quetglas, EG; Sádaba, B | 1 |
| Brandon, E; da Silva, AA; do Carmo, JM; Dubinion, J; Hall, JE; Kanyicska, B | 1 |
| Cheah, PY; Chee, C; Chong, WL; Khan, NA; Leong, WS; Liong, KK; Liong, ML; Low, BY; Yuen, KH | 1 |
| Chang, CH; Huang, SW; Wang, CJ | 2 |
| Rich, KT; Safranek, S | 1 |
| Akpolat, N; Ilhan, N; Kutlu, S; Onur, R; Seckin, D; Tasdemir, C | 1 |
| Kelly, BC; Perri, AJ; Speck, LM; Wilkerson, MG | 1 |
| Chancellor, MB; de Groat, WC; Kaiho, Y; Kamo, I; Miyazato, M; Sugaya, K; Yoshimura, N | 1 |
| Mamalis, N | 1 |
| Cho, MC; Kim, SW; Ku, JH; Paick, JS; Song, SH | 1 |
| Cheng, XR; Hua, CX; Hua, L; Huang, Y; Kang, J; Li, N; Li, YS; Liu, H; Ming, GH; Pang, HM; Wang, L; Wu, Y; Xu, L; Xu, ZM | 1 |
| Bar-Yosef, Y; Kaver, I; Laufer, M; Mabjeesh, NJ; Matzkin, H; Neulander, EZ | 1 |
| Mir, S; Peever, JH; Schwarz, PB; Yee, N | 1 |
| Chang, KL; Cheng, HL; Chih, TT; Hsieh, BS; Hu, YC; Huang, LW; Shyu, HW; Su, SJ | 1 |
| Cho, MC; Ku, JH; Paick, JS | 1 |
| Christelli, E; Karayannacos, P; Kyroudi-Voulgari, A; Mitropoulos, D; Zervas, A | 1 |
| An, GH; Cho, YW; Choa, YH; Kim, MJ; Lee, HJ; Park, K; Park, SS | 1 |
| Feng, YW; Yang, T; Zhang, XQ | 1 |
| Endeshaw, Y; Johnson, TM; Nagamia, Z; Ouslander, JG; Vaughan, CP | 1 |
| Chatterjee, M; Gupta, D; Gupta, S; Nanda, K; Ray, A; Singh, R; Tiwar, A | 1 |
| Chen, G; Liu, H; Liu, P; Liu, Z; Mao, G; Na, Y; Qin, X; Wang, B; Wang, X; Xu, X | 1 |
| Angelilli, A; De Moraes, CG; Liebmann, JM; Palmiero, PM; Prata, TS; Ritch, R; Sbeity, Z | 1 |
| Chen, GL; Liu, HP; Liu, P; Xu, XP | 1 |
| Cirilli, R; Ferretti, R; Gallinella, B; La Torre, F; Mosca, A; Turchetto, L; Zanitti, L | 1 |
| Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X | 1 |
| Deshpande, SB; Singh, SK | 1 |
| Fu, HY; Nie, JF; OuYang, LQ; Wu, HL; Yu, RQ; Zhang, Y; Zou, HY | 1 |
| Abraham, MK; Damisetti, KR; Kedari, PM; Narayanan, T; Nasir, AR; Puzhankara, R; Sudarsanan, B; Unnithan, GR | 1 |
| Hoyano, Y; Kobayashi, S; Kusama, H; Maruyama, K; Tomiyama, Y; Yamazaki, Y | 1 |
| Kakumoto, M; Kobayashi, H; Ohnishi, N; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y; Yokoyama, T | 1 |
| Li, HJ; Li, HZ; Yan, S; Zhang, XY | 1 |
| Hammad, FT; Kaya, MA | 1 |
| Chen, W; Dong, Z; Gao, W; Liu, Y; Wang, Z; Yang, K | 1 |
| Blaivas, JG | 1 |
| Jiang, MH; Liu, HL; Wu, GC | 1 |
| Combs, AJ; Glassberg, KI; Horowitz, M; Van Batavia, JP | 1 |
| Li, S; Lu, A; Wang, Y | 1 |
| Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA | 1 |
| Friedman, GD; Habel, LA; Udaltsova, N | 1 |
| Choi, YW; Jeong, SH; Lee, J; Nguyen, KV; Park, JS; Shim, JY; Shin, S; Yoon, JH | 1 |
| Alsene, KM; Bakshi, VP; Fallace, K | 1 |
| Cain, CK; Cunha, C; Hou, M; Lazzaro, SC; LeDoux, JE | 1 |
| Duffin, J; Peever, J; Tadjalli, A | 1 |
| Chatziralli, IP; Sergentanis, TN | 1 |
| Choi, du H; Chu, KR; Jeong, SH; Kim, NA; Shin, S; Truong, NK | 1 |
| Alan, C; Eren, AE; Ersay, AR; Ertung, Y; Kırılmaz, B; Koçoğlu, H | 1 |
| Krome, S | 1 |
| Choi, YW; Jeong, SH; Park, JS; Shim, JY | 1 |
| Du, H; He, L; Ren, J; Wang, S | 1 |
| Esmaeili, S; Farzan, A; Ghodsi, S; Heidari Nejad, S; Mokhtari, G; Shakiba, M | 1 |
| Casuccio, A; Cillino, G; Cillino, S; Pavone, C; Spitale, E | 1 |
| Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR | 1 |
| Hill, TM; McEwen, C; Sherman, JJ; Welch, RW | 1 |
| Ecke, LE; Elmer, GI; Suto, N | 1 |
| Choi, du H; Jeong, SH; Khoa Viet Truong, N; Shin, S | 1 |
| Armstrong, SP; Ayoub, MA; Mustafa, S; Pfleger, KD; See, HB; Seeber, RM; Ventura, S; White, CW | 1 |
| Ong, CT; Sung, SF; Tong, SH; Wu, CS | 1 |
| Anastasiou, I; Deliconstantinos, G; Kyroudi-Voulgari, A; Mitropoulos, D; Patris, E; Perea, D | 1 |
| Afzali, S; Ghaleiha, A; Matinnia, N; Shahidi, KM | 1 |
| Buzueva, II; Filyushina, EE; Lazarev, VA; Merkel, AL; Shmerling, MD; Yakobson, GS | 1 |
| Han, J; Liu, H; Liu, M; Wang, X; Yang, M; Zhang, D; Zhang, Y; Zhao, T | 1 |
| Engeland, WC; Fink, GD; Guzman, PA; Osborn, JW; Veitenheimer, BJ | 1 |
| Chancellor, MB; de Groat, WC; Miyazato, M; Oshiro, T; Saito, S; Yoshimura, N | 1 |
| Chao, WF; Huang, XK; Liang, P; Liu, JW; Wang, L; Wang, QT; Yang, H; Yang, W; Zhou, P | 1 |
| Mago, R; Rovner, BW; Thase, ME | 1 |
| Biondi, M; Carlone, C; Pallagrosi, M; Salviati, M; Todini, L; Valeriani, G | 1 |
| Haagsman, AN; Kirpensteijn, J; Kummeling, A; Mesu, SJ; Moes, ME | 1 |
| Ahmed, S; El Zohny, SA; Mohamed, NA | 1 |
| Araki, M; Araki, T; Monden, K | 1 |
| Davidescu, L; Mocanu, C; Puscasu, C | 1 |
| Cheng, FY; Lü, HX; Zhang, ZH; Zhou, JP | 1 |
| Cao, C; Chen, X; Ding, Y; Dong, M; Finci, L; Li, X; Li, Y; Liu, L; Wang, JH; Wang, T; Zhao, C | 1 |
| Kagan, OF; Kheĭfets, VKh; Sosnovskiĭ, SO | 2 |
| Li, AP; Peng, H; Peng, JD; Zhang, J; Zhou, MQ | 1 |
| Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
| Fisher, SA; Reho, JJ | 1 |
| Liang, K; Wang, J; Xu, Z; Yan, D | 1 |
| Asano, K; Egawa, S; Furuta, A; Kimura, S; Suzuki, Y; Yoshimura, N | 1 |
| Creta, M; Ficarra, V; Fusco, F; Giannarini, G; Longo, N; Mirone, V; Novara, G; Palmieri, A; Verze, P | 1 |
| Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C | 1 |
| He, F; Li, GZ; Liu, N; Man, LB | 1 |
| Jerončić, A; Papeš, D; Pasini, M | 1 |
| Ferrando-Castagnetto, F; Lluberas, N; Martínez, F; Vidal Margenat, A; Vignolo, G | 1 |
| Daneshmand, S; Shamie, N; Zhang, Y | 1 |
| Anoopkumar-Dukie, S; Batty, M; Chess-Williams, R; Christie, D; Forbes, A; McDermott, CM; Pugh, R; Rathinam, I; Simmonds, J; Spencer, B; Walker, E | 1 |
| Belayneh, M; Korownyk, C | 1 |
| Åkerström, T; Egginton, S; Hansen, JB; Hellsten, Y; Iepsen, UW; Madsen, M; Mortensen, SP; Munch, GDW; Pedersen, BK | 1 |
| Afanas'ev, RV; Bukhtiyarov, IV; Galkin, AA; Komarova, SN; Kovtun, VY; Semenova, LA; Ushakov, IB; Vasin, MV | 1 |
| Hammad, MA; Omar, MA; Salman, BI | 2 |
| Epstein, MP; Foster, SL; Pitts, EG; Schmidt, KT; Schroeder, JP; Smith, BM; Squires, K; Weinshenker, D | 1 |
| Amiri, M; Eskandari, H; Nekoueian, K; Sefid-Sefidehkhan, Y; Sillanpaa, M | 1 |
| Becker, CG; Becker, T; Boyd, PJ; Carter, RN; Gillingwater, TH; Graham, LC; Groen, EJN; Heath, PR; Highley, JR; Morton, NM; Motyl, AAL; Powis, RA; Shorrock, HK; Thomson, D; Thomson, SR; Tu, WY; Wishart, TM | 1 |
| Daniyal, M; Mohiuddin, E; Nadeem, HMR; UdDin, S; Usmanghani, K | 1 |
| Dobrzański, G; Kwiatkowska, K; Pradel, K; Przewłocki, R; Solecki, WB; Szklarczyk, K | 1 |
| Chen, N; Feng, B; Shao, Q; Wang, XS; Wu, S; Xia, J; Yuan, Y | 1 |
| Chen, YT; He, Q; Li, H; Liao, BH; Liu, QY; Wang, KJ; Yang, TX | 1 |
| Han, WJ; Liu, P; Sun, JM | 1 |
| Derayea, SM; Hammad, MA; Mohamed, AA; Mohamed, AI; Omar, MA | 1 |
| Luo, SB; Meng, ZC; Zhang, JY; Zhang, XY | 1 |
| Jalilian, Z; Nezhadali, A; Roushani, M | 1 |
| Anderson, CD; Ge, Y; Granger, JP; Haynes, BP; Spradley, FT | 1 |
| Gholamrezaie, HR; Hosseinkhani, A; Mishan, MA; Mohseni-Rad, H; Razzaghdoust, A | 1 |
| Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C | 1 |
| Foltynie, T | 1 |
| Daraei, B; Pashaei, Y; Shekarchi, M | 1 |
| Aboukhashaba, A; Fainberg, J; Gaffney, C; Kashanian, J; Khan, A; Pierce, H | 1 |
| Hori, Y; Ohyama, K; Sugiura, M | 1 |
| Amano, T; Fujii, N; Inoue, Y; Kenny, GP; Kondo, N | 1 |
| Ju, M; Qu, J; Wu, W; Yu, X; Zheng, J | 1 |
| ElMasry, MS; Hassan, WS; Hendawy, HAM; Ibrahim, AM; Shalaby, A | 1 |
| Enesei, D; Fekete, S; Kapui, I; Kormány, R | 1 |
| Chang, Y; Ji, Q; Li, F; Liu, C; Wang, Y; Zhang, X | 1 |
| Dahm, P; Hwang, EC; Koziarz, A; Kuntz, GM; Oestreich, MC; Sathianathen, NJ; Scales, CD; Vernooij, RW | 1 |
| Deng, SL; Lian, ZX; Tang, ZR; Yu, K | 1 |
| Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ | 1 |
| Gan, T; Gao, W; Gong, Y; Jiang, C; Jiang, L; Jiang, X; Ma, R; Shen, J; Wang, X; Ye, J; Zhang, M | 1 |
| Cai, C; Kilari, S; Misra, S; Sharma, A; Simeon, M; Singh, A; van Wijnen, AJ; Zhao, C | 1 |
| DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A | 1 |
| Fan, LL; Gan, CY; Li, MP; Mai, G; Shen-Tu, JZ; Wu, T; Zhang, PW | 1 |
| Brinker, AN; Ernst, SE; Liu, L; Magnotta, VA; Narayanan, NS; Rauckhorst, AJ; Schultz, JL; Simmering, JE; Taylor, EB; Tayyari, F; Uc, EY; Welsh, MJ; Xu, J | 1 |
| Chen, X; Han, L; Hu, Z; Li, C; Li, X; Liu, J; Wu, T; Zhao, W; Zhou, J | 1 |
| Hill, TE | 1 |
| Choudhury, SR; Karmakar, S; Mohanbhai, SJ; Sardoiwala, MN | 1 |
| Becker, CG; Becker, T; Carroll, E; Chaytow, H; Faller, KME; Gillingwater, TH; Gordon, D; Huang, YT; Smith, HL; Talbot, K; van der Hoorn, D | 1 |
74 review(s) available for terazosin and prazosin
| Article | Year |
|---|---|
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
Topics: Animals; Humans; Molecular Biology; Molecular Structure; Radioligand Assay; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1995 |
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Male; Prazosin; Prostatic Hyperplasia; United States | 1992 |
[Prostatic adenoma: new drugs, new surgical techniques].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatectomy; Prostatic Hyperplasia; Stents | 1992 |
Terazosin: a new alpha adrenoceptor blocking drug.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Drug Therapy, Combination; Hemodynamics; Humans; Hypertension; Prazosin | 1992 |
Alpha-blocker therapy of hypertension. An unfulfilled promise.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
Topics: Adrenergic alpha-Antagonists; Age Factors; Antihypertensive Agents; Dose-Response Relationship, Drug; Half-Life; Humans; Hypertension; Kidney Failure, Chronic; Meta-Analysis as Topic; Prazosin | 1991 |
Antihypertensive therapy: taking lipids into consideration.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazines; Calcium Channel Blockers; Coronary Disease; Diuretics; Drug Therapy, Combination; Humans; Hypertension; Incidence; Lipids; Prazosin; Risk Factors; Sodium Chloride Symporter Inhibitors | 1991 |
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Humans; Hypertension; Prazosin; Verapamil | 1991 |
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1991 |
Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Carbachol; Humans; Male; Muscle Contraction; Phenylephrine; Prazosin; Prostatic Hyperplasia; Quinoxalines | 1990 |
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Humans; Male; Middle Aged; Organ Size; Prazosin; Prostate; Prostatic Hyperplasia; Urination | 1991 |
Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Pressure; Clonidine; Doxazosin; Humans; Hypertension; Prazosin | 1987 |
Terazosin: a new antihypertensive agent with favorable effects on lipids.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Humans; Hypertension; Lipids; Prazosin | 1989 |
Blood pressure and lipid lowering effects of terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Humans; Hypertension; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Prazosin | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Prazosin; Random Allocation | 1986 |
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hypertension; Kinetics; Middle Aged; Prazosin | 1987 |
Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Heart Failure; Humans; Hypertension; Prazosin | 1988 |
New drugs of 1987--Part II.
Topics: Anti-Arrhythmia Agents; Clofazimine; Drug Therapy; Guanfacine; Guanidines; Humans; Lovastatin; Phenylacetates; Prazosin; Zidovudine | 1988 |
[Terazosine in the treatment of benign prostatic hypertrophy].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Flutamide; Humans; Male; Prazosin; Prostatic Hyperplasia | 1993 |
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics | 1995 |
Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Drug Therapy, Combination; Finasteride; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Oxidoreductases; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 1995 |
[New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Rats; Urinary Bladder Neck Obstruction; Urodynamics | 1995 |
The role of alpha 1-blockade in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aging; Clinical Trials as Topic; Humans; Male; Phenoxybenzamine; Prazosin; Prostatectomy; Prostatic Hyperplasia | 1993 |
Medical therapy for benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Anilides; Clinical Trials as Topic; Humans; Male; Nitriles; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Tosyl Compounds | 1993 |
Alpha 1-blockade in the management of hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Humans; Hypertension; Prazosin; Receptors, Adrenergic, alpha-1 | 1993 |
Pharmacology of terazosin: an alpha 1-selective blocker.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Half-Life; Humans; Prazosin; Receptors, Adrenergic, alpha; Sympathetic Nervous System; Vasodilator Agents | 1993 |
Adrenergic mechanisms in left ventricular hypertrophy: significance and clinical implications.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Models, Biological; Prazosin | 1993 |
Long-term efficacy and safety of terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Prazosin; Time Factors | 1993 |
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Doxazosin; Half-Life; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Vasodilation | 1996 |
Measures of Proscar, Hytrin, and Cardura side effects.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.
Topics: Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prevalence; Prostatectomy; Prostatic Hyperplasia; Severity of Illness Index; Treatment Outcome | 1997 |
Prostatic alpha 1-adrenoceptors and uroselectivity.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Humans; Male; Prazosin; Prostate; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1997 |
Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Clinical Trials as Topic; Dizziness; Humans; Hypotension; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
[Terazosin].
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia | 1998 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient Selection; Plant Extracts; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Female; Humans; Hypertension; Male; Multicenter Studies as Topic; Prazosin; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic | 1998 |
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 1998 |
Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizziness; Dose-Response Relationship, Drug; Doxazosin; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urologic Diseases | 1999 |
[Evaluation and repair of bladder function after spinal cord injuries].
Topics: Adrenergic alpha-Antagonists; Animals; Electric Stimulation Therapy; Humans; Prazosin; Spinal Cord Injuries; Urinary Bladder; Urinary Bladder, Neurogenic | 1997 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
Development of a new in vitro model for the study of benign prostatic hyperplasia.
Topics: Cell Differentiation; Coculture Techniques; Epithelial Cells; Humans; Male; Microscopy, Electron; Models, Biological; Prazosin; Prostate; Prostatic Hyperplasia; Stromal Cells | 2000 |
Clinical perspective on apoptosis in the management of the BPH patient.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Humans; Male; Muscle, Smooth; Prazosin; Prostatic Hyperplasia; Stromal Cells; Treatment Outcome | 2000 |
[Drugs for the treatment of benign prostatic hypertrophy].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Muscle, Smooth; Plant Extracts; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Serenoa; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urodynamics | 2000 |
Benign prostatic hyperplasia. The Saudi perspective in the year 2000.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Distribution; Age of Onset; Aged; Finasteride; Humans; Male; Mass Screening; Middle Aged; Needs Assessment; Population Surveillance; Prazosin; Prostatectomy; Prostatic Hyperplasia; Risk Factors; Saudi Arabia; Treatment Outcome; Urology; Workload | 2000 |
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Bayes Theorem; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Urination Disorders | 2001 |
Terazosin, doxazosin, and prazosin: current clinical experience.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha | 2001 |
5alpha-reductase inhibitors: what role should they play?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic | 2001 |
Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Tumor Cells, Cultured | 2000 |
Terazosin for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Antineoplastic Agents; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 2002 |
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Structure-Activity Relationship; Treatment Outcome; Urinary Bladder Neck Obstruction | 2003 |
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Treatment Outcome | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2003 |
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
Topics: Biological Availability; Carbamazepine; Cefuroxime; Chemistry Techniques, Analytical; Crystallography; Decision Trees; Drug Approval; Drug Stability; Drugs, Generic; Enalapril; Humans; Molecular Conformation; Phase Transition; Prazosin; Quality Control; Ranitidine; Solubility; Sulfonamides; Technology, Pharmaceutical; Therapeutic Equivalency; Torsemide; United States; United States Food and Drug Administration; Warfarin | 2004 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoikis; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Sulfonamides; Tamsulosin | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
[Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Hypertension; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 2007 |
FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Practice Guidelines as Topic; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Treatment Outcome | 2008 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2008 |
Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin | 2009 |
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; Incidence; Intraoperative Complications; Iris; Iris Diseases; Odds Ratio; Phacoemulsification; Prazosin; Quinazolines; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2011 |
[How effective is finasteride?].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin | 2011 |
α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Indoles; Male; Naphthalenes; Piperazines; Prazosin; Prostatism; Quinazolines; Severity of Illness Index; Sulfonamides; Tamsulosin; Urodynamics | 2016 |
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Doxazosin; Female; Humans; Male; Prazosin; Prostatic Neoplasms | 2016 |
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptoms; Male; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic | 2016 |
A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Calcium Channel Blockers; Combined Modality Therapy; Humans; Kidney Calculi; Lithotripsy; Network Meta-Analysis; Nifedipine; Prazosin; Sulfonamides; Terpenes; Treatment Outcome; Ureteral Calculi; Urinary Calculi | 2017 |
Glycolysis as a therapeutic target for Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Drug Delivery Systems; Glycolysis; Humans; Parkinson Disease; Prazosin | 2019 |
Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxazosin; Humans; Indoles; Kidney Calculi; Lithotripsy; Middle Aged; Prazosin; Quinazolines; Randomized Controlled Trials as Topic; Tamsulosin; Ureteral Calculi | 2020 |
156 trial(s) available for terazosin and prazosin
| Article | Year |
|---|---|
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 1992 |
Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Single-Blind Method; Urination | 1992 |
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Protocols; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 1992 |
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Male; Prazosin; Prostatic Hyperplasia; United States | 1992 |
Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Single-Blind Method; Urination | 1992 |
A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypertension; Male; Middle Aged; Physical Exertion; Prazosin; Randomized Controlled Trials as Topic | 1992 |
Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Methyclothiazide; Middle Aged; Prazosin | 1992 |
Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prazosin | 1992 |
Double-blind placebo-controlled trial of terazosin effect on blood pressure and urinary output of dopamine in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Dopamine; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Urination | 1992 |
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Prazosin; Prostatic Hyperplasia | 1992 |
Efficacy of terazosin in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Drug Evaluation; Humans; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia; Time Factors; Urinary Retention | 1992 |
[A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urination Disorders | 1992 |
A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Blood Pressure; Cholesterol; Female; Hospitals; Humans; Hypertension; Male; Prazosin | 1991 |
Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1991 |
Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Prazosin; Time Factors | 1991 |
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Humans; Hypertension; Prazosin; Verapamil | 1991 |
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1991 |
A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cholesterol; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1991 |
The influence of food on the oral bioavailability of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Biological Availability; Food; Humans; Middle Aged; Prazosin | 1991 |
Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic | 1990 |
A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics | 1990 |
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Humans; Male; Middle Aged; Organ Size; Prazosin; Prostate; Prostatic Hyperplasia; Urination | 1991 |
Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aging; Blood Pressure; Humans; Kinetics; Middle Aged; Prazosin; Pulse | 1987 |
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscle Contraction; Muscle, Smooth; Prazosin; Prostate; Prostatic Hyperplasia; Radioligand Assay; Random Allocation; Receptors, Adrenergic, alpha | 1988 |
Clinical experience: symptomatic management of BPH with terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Multicenter Studies as Topic; Placebos; Prazosin; Prostatic Hyperplasia; Time Factors; Urodynamics | 1988 |
The effects of terazosin and methyclothiazide on blood pressure and serum lipids.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Apolipoproteins; Blood Pressure; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lipids; Male; Methyclothiazide; Middle Aged; Multicenter Studies as Topic; Prazosin; Random Allocation; Triglycerides | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Antihypertensive effectiveness of terazosin: a new long-acting alpha-adrenergic inhibitor.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Piperazines; Prazosin | 1985 |
Clinical trials with terazosin. General methods.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Piperazines; Prazosin; Random Allocation; Research Design | 1986 |
Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Piperazines; Posture; Prazosin; Random Allocation | 1986 |
Effect of withdrawal of terazosin therapy in patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Dizziness; Female; Follow-Up Studies; Headache; Humans; Hypertension; Male; Middle Aged; Piperazines; Prazosin; Random Allocation; Substance Withdrawal Syndrome | 1986 |
Comparative trials of terazosin with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Piperazines; Prazosin; Random Allocation | 1986 |
Cumulative experience with terazosin administered in combination with diuretics.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Posture; Prazosin; Random Allocation | 1986 |
Experience with terazosin administered in combination with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Posture; Prazosin; Random Allocation | 1986 |
Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Posture; Prazosin; Pulse; Random Allocation | 1986 |
Efficacy of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Antihypertensive Agents; Black or African American; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Prazosin; Random Allocation; White People | 1986 |
Effect of terazosin on serum lipids.
Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Lipids; Lipoproteins, VLDL; Piperazines; Prazosin; Random Allocation; Triglycerides | 1986 |
Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Injections, Intravenous; Kinetics; Middle Aged; Piperazines; Prazosin; Pulse; Random Allocation | 1986 |
Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hypertension; Lipoproteins; Male; Methyclothiazide; Middle Aged; Prazosin | 1986 |
Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Prazosin; Random Allocation | 1986 |
Efficacy and safety of doxazosin in hypertension therapy.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1987 |
Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1987 |
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hypertension; Kinetics; Middle Aged; Prazosin | 1987 |
Terazosin for hypertension.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Prazosin | 1987 |
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Pulse; Time Factors | 1988 |
Terazosin in mild hypertension: experience in open trials.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1987 |
Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; United States | 1987 |
Effect of age on the pharmacokinetics of orally and intravenously administered terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Aging; Creatinine; Female; Humans; Injections, Intravenous; Male; Middle Aged; Prazosin | 1988 |
Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1988 |
Long-term BP monitoring in the evaluation of antihypertensive therapy.
Topics: Adult; Aged; Blood Pressure; Circadian Rhythm; Drug Evaluation; Humans; Hypertension; Male; Middle Aged; Piperazines; Prazosin; Time Factors | 1983 |
Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urodynamics | 1993 |
Use of terazosin in prostatodynia and validation of a symptom score questionnaire.
Topics: Adrenergic alpha-Antagonists; Adult; Humans; Logistic Models; Male; Middle Aged; Pain; Pain Measurement; Prazosin; Prospective Studies; Prostatic Diseases; Prostatic Hyperplasia; Prostatitis; Surveys and Questionnaires; Urodynamics | 1994 |
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Humans; Hypertension; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Treatment Outcome; United States | 1994 |
Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Middle Aged; Prazosin; Primary Health Care; Prostatic Hyperplasia; Severity of Illness Index | 1994 |
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Follow-Up Studies; Humans; Male; Prazosin; Prostatic Hyperplasia; Time Factors; Urodynamics | 1995 |
Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Prazosin; Prostatectomy; Prostatic Hyperplasia; Severity of Illness Index | 1995 |
Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Posture; Prazosin; Verapamil | 1995 |
Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Dizziness; Double-Blind Method; Female; Headache; Humans; Middle Aged; Pilot Projects; Placebos; Prazosin; Treatment Outcome; Urinary Incontinence, Stress; Urination Disorders | 1995 |
Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Female; Glucose; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Prazosin; Prospective Studies | 1994 |
[The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura].
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migraine Disorders; Prazosin; Pyrrolidines; Surveys and Questionnaires; Time Factors; Vasodilator Agents | 1994 |
[Pressure and metabolic effects of terazosin in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Factor; Blood Glucose; Double-Blind Method; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Prazosin | 1994 |
Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Double-Blind Method; Enalapril; Exercise Test; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin; Rest; Stress, Psychological | 1993 |
Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy.
Topics: Adrenergic alpha-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Ejaculation; Humans; Male; Middle Aged; Prazosin; Psychotherapy; Quinazolines; Sexual Dysfunctions, Psychological | 1995 |
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Pilot Projects; Prazosin; Prostatic Hyperplasia; Urodynamics | 1995 |
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Survival Analysis; Time Factors; Treatment Failure; United States; Urodynamics | 1996 |
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Cost-Benefit Analysis; Diagnosis-Related Groups; Health Resources; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Regression Analysis; Treatment Outcome; United States | 1996 |
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics | 1996 |
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Canada; Double-Blind Method; Humans; Hypotension; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urodynamics | 1996 |
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Oxidoreductases; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urodynamics | 1996 |
Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Arteries; Blood Pressure; Cholesterol; Doxazosin; Female; Heart Rate; Humans; Hypertension; In Vitro Techniques; Lipids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prazosin; Triglycerides | 1996 |
The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Safety; Single-Blind Method | 1996 |
Terazosin vs finasteride for BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebos; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome; Urination | 1996 |
Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride.
Topics: Adrenergic alpha-Antagonists; Adult; Area Under Curve; Blood Pressure; Dihydrotestosterone; Drug Interactions; Enzyme Inhibitors; Finasteride; Half-Life; Heart Rate; Humans; Male; Middle Aged; Prazosin; Testosterone | 1996 |
Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics | 1997 |
Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics | 1997 |
Influence of prostate size on terazosin efficacy.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urodynamics | 1997 |
Beneficial effect of alpha-blocker on hemorheology in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Viscosity; Erythrocyte Deformability; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Prazosin | 1997 |
[Raynaud's phenomenon: effects of terazosin].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Female; Humans; Male; Middle Aged; Prazosin; Raynaud Disease; Ultrasonography | 1997 |
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Longitudinal Studies; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Time Factors | 1997 |
Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome; Urination | 1997 |
[Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urodynamics | 1997 |
The nature of detrusor bladder neck dyssynergia in non-neurogenic bladder dysfunction.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Humans; Male; Middle Aged; Muscle, Smooth; Prazosin; Pressure; Urinary Bladder Diseases; Urodynamics | 1997 |
Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Animals; Chromatography, High Pressure Liquid; Cloning, Molecular; Cross-Over Studies; Humans; Male; Placebos; Prazosin; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Single-Blind Method; Substrate Specificity; Sulfonamides; Tamsulosin; Transfection | 1998 |
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Drug Administration Schedule; Heart Rate; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urinary Retention; Urodynamics; Vertigo | 1998 |
Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Dizziness; Double-Blind Method; Heart Rate; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Nausea; Posture; Prazosin | 1998 |
The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Treatment Outcome | 1998 |
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aging; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cerebrovascular Disorders; Circadian Rhythm; Cross-Over Studies; Female; Hemodynamics; Humans; Hypertension; Male; Nifedipine; Prazosin; Quality of Life | 1998 |
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Retrospective Studies; Single-Blind Method | 1998 |
Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Area Under Curve; Doxazosin; Drug Interactions; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Time Factors | 1998 |
Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and paediatric spinal cord injury patients manifesting recurrent dysreflexic episodes.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Autonomic Nervous System Diseases; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Recurrence; Reflex, Abnormal; Spinal Cord Injuries; Treatment Outcome | 1998 |
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Diathermy; Humans; Male; Microwaves; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Treatment Failure; Urodynamics | 1999 |
Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cross-Over Studies; Drug Interactions; Hemodynamics; Humans; Male; Phenylephrine; Placebos; Prazosin; Single-Blind Method; Sulfonamides; Tamsulosin; Vasoconstriction | 1999 |
Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Treatment Outcome; United States; United States Department of Veterans Affairs | 1999 |
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 1999 |
Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Clonidine; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin | 1997 |
A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Blood Pressure; Blood Vessels; Cross-Over Studies; Dose-Response Relationship, Drug; Fingers; Hand; Heart Rate; Humans; Male; Phenylephrine; Prazosin; Pulse; Regional Blood Flow; Sulfonamides; Tamsulosin; Vasoconstriction; Vasoconstrictor Agents; Veins | 1999 |
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Hypotension; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Single-Blind Method; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder Neck Obstruction | 1998 |
[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
Topics: Aged; Coronary Disease; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Risk; Time Factors; Treatment Outcome; Urodynamics | 1999 |
Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Adult; Humans; Male; Prazosin; Prospective Studies; Prostatitis; Sulfonamides; Tamsulosin | 1999 |
Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Fasting; Female; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Postprandial Period; Prazosin; Probability; Single-Blind Method | 1999 |
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 2000 |
A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Single-Blind Method; Sulfonamides; Tamsulosin | 2000 |
Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urodynamics | 2000 |
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Double-Blind Method; Humans; Male; Prazosin; Prostatic Hyperplasia; Quality of Life; Quinazolines; Severity of Illness Index | 2000 |
[Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Humans; Male; Practice Patterns, Physicians'; Prazosin; Prostatic Hyperplasia; Urination Disorders | 2000 |
The relationship between terazosin dose and blood pressure response in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin | 2000 |
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Follow-Up Studies; Humans; Male; Microwaves; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life | 2001 |
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urination Disorders | 2001 |
[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 2001 |
Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Prazosin; Prostatitis; Treatment Outcome | 2001 |
The efficacy of terazosin for treating benign prostatic hyperplasia: a multicentre clinical trial.
Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urinary Retention | 2002 |
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Palladium; Postoperative Complications; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy, Conformal; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention; Urination Disorders | 2002 |
[Effects of terazosine and atenolol on serum lipids in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Middle Aged; Prazosin; Prospective Studies; Triglycerides | 2002 |
[Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Combined Modality Therapy; Humans; Hyperthermia, Induced; Male; Middle Aged; Pain; Pain Management; Prazosin; Prostatitis | 2002 |
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; Prazosin; Prostatitis; Syndrome | 2003 |
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Urination Disorders | 2003 |
Effect of terazosin on blood pressure and serum lipids.
Topics: Antihypertensive Agents; Blood Pressure; Essential Hypertension; Humans; Hypercholesterolemia; Hypertension; Lipid Metabolism; Prazosin; Prospective Studies | 1999 |
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia; Reference Values; Treatment Outcome; Urination Disorders | 2003 |
[Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Endothelium, Vascular; Female; Fibrin Fibrinogen Degradation Products; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; Prazosin | 2003 |
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 2004 |
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia | 2004 |
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Pelvic Pain; Prazosin; Prostatitis; Quality of Life; Research Design; Syndrome; Time Factors | 2004 |
The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Doxazosin; Female; Humans; Male; Middle Aged; Pain Measurement; Prazosin; Sulfonamides; Tamsulosin; Treatment Outcome; Ureteral Calculi | 2005 |
Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Phytotherapy; Plants, Medicinal; Prazosin; Prostatic Hyperplasia; Urodynamics | 2005 |
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study.
Topics: Adrenergic alpha-Antagonists; Adult; Combined Modality Therapy; Humans; Magnetics; Male; Middle Aged; Pelvic Pain; Pilot Projects; Prazosin; Prostatitis; Syndrome; Treatment Outcome | 2006 |
Efficacy of terazosin as a facilitator agent for expulsion of the lower ureteral stones.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Female; Humans; Male; Middle Aged; Prazosin; Treatment Outcome; Ureteral Calculi | 2006 |
The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.
Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Middle Aged; Pilot Projects; Prazosin; Prospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination; Urodynamics | 2006 |
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prazosin; Prospective Studies; Prostatic Hyperplasia; Tolterodine Tartrate; Urination Disorders | 2007 |
Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Dizziness; Drugs, Generic; Edema; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Taiwan; Therapeutic Equivalency | 2007 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome | 2007 |
High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study.
Topics: Adrenergic alpha-Antagonists; Aged; Asian People; Blood Pressure; Humans; Hypertension; Korea; Male; Middle Aged; Prazosin; Prospective Studies; Prostate; Treatment Outcome; Urodynamics; Urologic Diseases | 2007 |
Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers.
Topics: Abdominal Pain; Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Algorithms; Area Under Curve; Blood Pressure; Chromatography, High Pressure Liquid; Dizziness; Dose-Response Relationship, Drug; Female; Half-Life; Headache; Heart Rate; Humans; Male; Prazosin; Tachycardia; Time Factors | 2008 |
Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Double-Blind Method; Female; Humans; Middle Aged; Prazosin; Urination Disorders | 2008 |
Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Female; Humans; Male; Middle Aged; Prazosin; Sulfonamides; Tamsulosin; Ureteral Calculi | 2008 |
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Prazosin; Sulfonamides; Torsemide; Treatment Outcome | 2007 |
[Efficacy of electroacupuncture in treating 93 patients with benign prostatic hyperplasia].
Topics: Aged; Aged, 80 and over; Electroacupuncture; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urination | 2008 |
Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Analgesics, Opioid; Buprenorphine; Colic; Combined Modality Therapy; Female; Humans; Lithotripsy; Male; Middle Aged; Pain; Pain Measurement; Pilot Projects; Prazosin; Prospective Studies; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Treatment Outcome; Ureteral Calculi | 2009 |
Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Male; Middle Aged; Prazosin; Prostatism | 2009 |
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Retention; Urodynamics | 2009 |
[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome].
Topics: Adult; Chlormezanone; Chronic Disease; Drug Therapy, Combination; Humans; Male; Middle Aged; Pain Measurement; Pelvic Pain; Prazosin; Prostatitis; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
[Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome].
Topics: Adult; Chronic Disease; Humans; Indomethacin; Ketoprofen; Male; Pelvic Pain; Prazosin; Prostatitis; Tromethamine | 2009 |
Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches.
Topics: Aged; Antineoplastic Agents; Humans; Logistic Models; Male; Medicine; Medicine, Chinese Traditional; Middle Aged; Phytotherapy; Plant Preparations; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Saxifragaceae; Surveys and Questionnaires; Urethra; Urination | 2010 |
Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Chi-Square Distribution; Double-Blind Method; Flank Pain; Hematuria; Humans; Iran; Nocturia; Pain Measurement; Placebo Effect; Prazosin; Prospective Studies; Stents; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ureteral Calculi; Urination Disorders | 2011 |
Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prazosin; Selective Serotonin Reuptake Inhibitors; Sertraline; Sweating; Treatment Outcome | 2013 |
Pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects.
Topics: Adult; Asian People; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Health; Humans; Male; Prazosin; Spectrometry, Fluorescence; Stereoisomerism; Young Adult | 2012 |
[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
Topics: Adult; Capsules; Chronic Disease; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Phytotherapy; Prazosin; Prostatitis; Treatment Outcome; Young Adult | 2012 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazosin; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Piperazines; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome | 2013 |
[Peculiarities of clinical course, diagnostics and treatment of overactive bladder in men older than 60 years].
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Prostatitis; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Humans; Levofloxacin; Male; Pelvic Pain; Prazosin; Prospective Studies; Prostatitis; Syndrome; Treatment Outcome; Urological Agents | 2016 |
Comparison of Anti BPH capsule (herbal) and Terazosin HCl in the treatment of benign prostate hyperplasia.
Topics: Adult; Aged; Aged, 80 and over; Capsules; Humans; Male; Middle Aged; Plant Extracts; Plant Preparations; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Surveys and Questionnaires | 2017 |
[Efficacy and safety of Tonglin Powder in the treatment of benign prostatic hyperplasia].
Topics: Adult; Aged; Aged, 80 and over; Drugs, Chinese Herbal; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Treatment Outcome | 2016 |
[Triple acupuncture at the Qugu acupoint as an adjunctive therapy for type-Ⅲ chronic prostatitis: Analysis of short- and long-term clinical effects].
Topics: Acupuncture Points; Acupuncture Therapy; Anti-Bacterial Agents; Chronic Disease; Chronic Pain; Combined Modality Therapy; Drug Therapy, Combination; Humans; Levofloxacin; Male; Pelvic Pain; Prazosin; Prostatitis; Quality of Life; Recurrence; Syndrome; United States; Urological Agents | 2017 |
Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Lithotripsy; Male; Nifedipine; Pain Measurement; Postoperative Complications; Prazosin; Quality of Life; Time Factors; Treatment Outcome; Ureteral Calculi; Ureteroscopy; Urethra | 2020 |
A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antihypertensive Agents; Carvedilol; Cross-Over Studies; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Prazosin; Prostatic Hyperplasia; Single-Blind Method | 2021 |
Bioequivalence study of two formulations of terazosin hydrochloride capsule in healthy Chinese subjects under fasting and fed conditions.
Topics: Area Under Curve; China; Chromatography, Liquid; Cross-Over Studies; Fasting; Healthy Volunteers; Humans; Prazosin; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency | 2022 |
A pilot to assess target engagement of terazosin in Parkinson's disease.
Topics: Adenosine Triphosphate; Dizziness; Humans; Parkinson Disease; Pilot Projects; Prazosin | 2022 |
362 other study(ies) available for terazosin and prazosin
| Article | Year |
|---|---|
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Calcium Channel Blockers; Cell Line; Cloning, Molecular; Dihydropyridines; Humans; Receptors, Adrenergic, alpha-1 | 1995 |
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amides; Animals; Binding, Competitive; Humans; Male; Middle Aged; Models, Chemical; Muscle, Smooth; Piperazines; Prazosin; Propylamines; Prostatic Hyperplasia; Rabbits; Rats; Structure-Activity Relationship; Urinary Bladder | 1997 |
4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Humans; Male; Organ Specificity; Prazosin; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Spinal Cord; Structure-Activity Relationship | 1998 |
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Biological Availability; Blood Pressure; Dogs; Drug Design; Drug Evaluation, Preclinical; GTP-Binding Proteins; Half-Life; Humans; In Vitro Techniques; Male; Microsomes; Piperidines; Prostate; Pyrimidinones; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Receptors, Opioid, mu; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Urethra | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Topics: Chemical Phenomena; Chemistry, Physical; Ligands; Models, Molecular; Molecular Conformation; Monte Carlo Method; Quantitative Structure-Activity Relationship; Receptors, Adrenergic, alpha-1; Solvents | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Computational approach to the basicity of a series of alpha1-adrenoceptor ligands in aqueous solution.
Topics: Chemical Phenomena; Chemistry, Physical; Computational Biology; Databases, Factual; Epinephrine; Guanidine; Hydrogen-Ion Concentration; Imidazoles; Kinetics; Ligands; Molecular Conformation; Norepinephrine; Receptors, Adrenergic, alpha-1; Solutions; Thermodynamics; Vasoconstrictor Agents; Water | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Molecular features of the prazosin molecule required for activation of Transport-P.
Topics: Antihypertensive Agents; Biological Transport, Active; Cells, Cultured; Molecular Structure; Neurons; Prazosin; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Molecular Structure; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Receptors, Angiotensin; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Dose-Response Relationship, Drug; Hypotension; Male; Molecular Structure; Piperazines; Pyrrolidinones; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship | 2015 |
The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Muscle, Smooth; Prazosin; Prostatic Hyperplasia; Staining and Labeling; Urination | 1992 |
Studies on the functional role of alpha-adrenoceptors in the cardiac sympathetic ganglia of the dog.
Topics: Animals; Dimethylphenylpiperazinium Iodide; Dogs; Electric Stimulation; Ganglia, Sympathetic; Heart; Heart Rate; Prazosin; Receptors, Adrenergic, alpha; Receptors, Nicotinic; Yohimbine | 1992 |
Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats.
Topics: Adrenergic alpha-Antagonists; Animals; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Kidney Glomerulus; Male; Nephrons; Prazosin; Rats; Rats, Inbred Strains; Renal Circulation | 1992 |
Alpha 1-adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain.
Topics: Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Brain; Dogs; Humans; In Vitro Techniques; Male; Prazosin; Prostate; Receptors, Adrenergic, alpha; Stereoisomerism | 1992 |
Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Biomarkers; Blood Pressure; Body Weight; Hemodynamics; Hypertension; Male; Methylhistidines; Muscle, Smooth, Vascular; Organ Size; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 1992 |
Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.
Topics: Adrenergic alpha-Antagonists; Adult; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Male; Phenylephrine; Prazosin; Receptors, Adrenergic, alpha | 1992 |
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 1992 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha | 1992 |
The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Florida; Follow-Up Studies; Hospitals, Military; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urodynamics | 1992 |
[Effect of terazosin on lower urinary tract function in the male decerebrate dog].
Topics: Animals; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Electromyography; Male; Muscle Contraction; Muscle, Smooth; Prazosin; Reflex; Urethra; Urinary Bladder; Urination | 1992 |
Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin.
Topics: Adolescent; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Humans; Hypertension; Middle Aged; Prazosin | 1992 |
Clinical model for antihypertensive therapy in the 1990s: the role of alpha1 blockade. Proceedings of a symposium. Irving, Texas, November 8-10, 1990.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Prazosin | 1991 |
Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
Topics: Adrenergic alpha-Antagonists; Cardiac Catheterization; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension; Injections, Intravenous; Male; Middle Aged; Prazosin; Time Factors; Vasodilator Agents; Ventricular Function, Left | 1991 |
Alpha 1-adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR.
Topics: Adrenergic alpha-Antagonists; Animals; Arterioles; Blood Pressure; Glomerular Filtration Rate; Heart Rate; Kidney Glomerulus; Male; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha; Reference Values; Regional Blood Flow; Renal Circulation; Vascular Resistance | 1991 |
Neuropeptide Y-induced intestinal absorption: mediation by alpha 2-adrenergic receptors.
Topics: Adrenergic alpha-Antagonists; Animals; Ileum; Intestinal Absorption; Neuropeptide Y; Prazosin; Rabbits; Receptors, Adrenergic, alpha; Water-Electrolyte Balance; Yohimbine | 1991 |
Binding characteristics of alpha 1-adrenoceptors in bovine prostate using a radioligand binding assay.
Topics: Adrenergic alpha-Antagonists; Animals; Cattle; Kinetics; Male; Membranes; Phentolamine; Prazosin; Prostate; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha; Tritium | 1991 |
Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Drug Tolerance; Heart Rate; Humans; Insulin; Iodine Radioisotopes; Lipoproteins; Male; Prazosin; Radioimmunoassay; Triglycerides | 1991 |
[Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Muscle Contraction; Muscle, Smooth; Norepinephrine; Prazosin; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Adrenergic, alpha; Yohimbine | 1991 |
Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Coronary Circulation; Exercise; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Prazosin; Rest | 1990 |
Efficacy of terazosin in the treatment of essential hypertension in blacks.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Black People; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Retrospective Studies | 1990 |
Effects of terazosin on serum lipid levels in hypertensive blacks.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Black People; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1990 |
Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Cardiomegaly; Drug Evaluation; Electrocardiography; Female; Heart Ventricles; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Plasma Volume; Prazosin; Renin | 1990 |
Inhibitory effects of catecholamines in the paravertebral sympathetic ganglia of the anesthetized dog.
Topics: Adrenergic alpha-Agonists; Anesthesia; Animals; Blood Pressure; Catecholamines; Clonidine; Dogs; Ganglia, Sympathetic; Hexamethonium Compounds; Male; Norepinephrine; Phenylephrine; Prazosin; Receptors, Adrenergic, alpha; Regional Blood Flow; Vascular Resistance; Yohimbine | 1990 |
[Effects of terazocin on hypertensive patients].
Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1990 |
Effects of pertussis toxin on alpha 1-agonist-mediated phosphatidylinositide turnover and myocardial cell hypertrophy in neonatal rat ventricular myocytes.
Topics: Adenosine Diphosphate Ribose; Animals; Animals, Newborn; Cell Division; Cells, Cultured; Inositol Phosphates; Myocardium; Norepinephrine; Pertussis Toxin; Phosphatidylinositols; Prazosin; Propranolol; Rats; Receptors, Adrenergic, alpha; Virulence Factors, Bordetella; Yohimbine | 1990 |
Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
Topics: Animals; Blood Pressure; Heart Rate; Ketanserin; Male; Prazosin; Rabbits; Receptors, Adrenergic, alpha; Receptors, Serotonin; Renal Circulation; Vasodilation | 1987 |
The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain.
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding Sites; Binding, Competitive; Cerebral Cortex; Dogs; Humans; Male; Middle Aged; Phenethylamines; Prazosin; Prostatic Hyperplasia; Tetralones; Yohimbine | 1988 |
The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urodynamics | 1989 |
Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Pilot Projects; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urodynamics | 1989 |
Alpha-blocking potencies of antihypertensive agents (prazosin, terazosin, bunazosin, SGB-1534 and ketanserin) having with quinazoline or quinazolinedione as assessed by radioligand binding assay methods in rat brain.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Brain; Cell Membrane; Clonidine; Dihydroalprenolol; Ketanserin; Male; Prazosin; Quinazolines; Radioligand Assay; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1989 |
The effects of the alpha 1-adrenergic antagonists terazosin and phentolamine on prostatic adenoma and urethra in vitro.
Topics: Adenoma; Adrenergic alpha-Antagonists; Humans; In Vitro Techniques; Male; Muscle Contraction; Phentolamine; Prazosin; Prostatic Neoplasms; Urethra | 1989 |
Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Prazosin; Renin-Angiotensin System; Time Factors | 1989 |
Renal hemodynamic responses to 5-hydroxytryptamine (5-HT): involvement of the 5-HT receptor subtypes in the canine kidney.
Topics: Adrenergic alpha-Antagonists; Animals; Dogs; Female; Ketanserin; Kidney; Male; Methysergide; Prazosin; Receptors, Serotonin; Renal Circulation; Renin; Serotonin | 1989 |
Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes.
Topics: Actins; Animals; Cardiomegaly; Cells, Cultured; Dose-Response Relationship, Drug; Isoproterenol; Myocardial Contraction; Norepinephrine; Prazosin; Propranolol; Rats; Receptors, Adrenergic, alpha; RNA, Messenger | 1987 |
Alpha 1-adrenergic blockade and cardiovascular pressor responses in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cardiovascular System; Drug Interactions; Electrolytes; Female; Heart Rate; Humans; Hypertension; Isoproterenol; Male; Middle Aged; Norepinephrine; Patient Compliance; Piperazines; Posture; Prazosin | 1986 |
Advances in the management of hypertension: focus on terazosin, a new alpha1-adrenergic antagonist. May 3-5, 1985, Boca Raton, Florida.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Piperazines; Prazosin | 1986 |
Pharmacology of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Chemical Phenomena; Chemistry; Dogs; Dose-Response Relationship, Drug; Female; Gerbillinae; Hemodynamics; Hypertension; Lipoproteins; Male; Piperazines; Prazosin; Rabbits; Rats; Rats, Inbred Strains | 1986 |
Pharmacokinetics of terazosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Blood Proteins; Chemical Phenomena; Chemistry; Female; Half-Life; Heart Failure; Humans; Hypertension; Infusions, Parenteral; Kinetics; Liver; Male; Middle Aged; Piperazines; Prazosin; Protein Binding; Rats | 1986 |
Long-term experience with terazosin for treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Piperazines; Prazosin | 1986 |
Overall safety of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Headache; Humans; Hypertension; Male; Middle Aged; Piperazines; Prazosin; Pulse; Syncope | 1986 |
Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Female; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Piperazines; Prazosin; Pulse | 1986 |
High-performance liquid chromatographic measurement of prazosin and terazosin in biological fluids.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Humans; Prazosin | 1986 |
The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Rest; Time Factors | 1986 |
[Alpha-adrenoceptor blocking action of terazosin].
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Aorta; Decerebrate State; Heart Rate; Male; Phentolamine; Prazosin; Rats; Rats, Inbred Strains; Vasodilator Agents; Yohimbine | 1986 |
[Antigenicity study of terazosin].
Topics: Adrenergic alpha-Antagonists; Anaphylaxis; Animals; Antigens; Drug Hypersensitivity; Female; Guinea Pigs; Immunoglobulin E; Male; Mice; Mice, Inbred Strains; Ovalbumin; Passive Cutaneous Anaphylaxis; Prazosin; Rats; Serum Albumin, Bovine; Species Specificity | 1987 |
Pharmacological characterization of the postsynaptic alpha-adrenoceptors in isolated canine mesenteric arteries and veins.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Dogs; Dopamine; Female; In Vitro Techniques; Male; Mesenteric Arteries; Mesenteric Veins; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Prazosin; Quinoxalines; Receptors, Adrenergic, alpha; Synapses; Yohimbine | 1987 |
[Effects of intravenous and intracerebroventricular terazosin, prazosin and clonidine on spontaneous sympathetic outflow in rats].
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Brain; Clonidine; Heart Rate; Injections, Intravenous; Injections, Intraventricular; Kidney; Male; Prazosin; Rats; Rats, Inbred Strains; Sympathetic Nervous System | 1987 |
Adrenergic and serotonergic receptor-blocking potencies of terazosin, a new antihypertensive agent, as assessed by radioligand binding assay.
Topics: Adrenergic alpha-Antagonists; Animals; Brain Chemistry; Dogs; In Vitro Techniques; Male; Prazosin; Radioligand Assay; Receptors, Adrenergic; Receptors, Serotonin | 1987 |
Hemodynamic recovery during simulated ventricular tachycardia: role of adrenergic receptor activation.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Female; Ganglia, Autonomic; Heart Ventricles; Hemodynamics; Hexamethonium Compounds; Hypotension; Male; Myocardial Contraction; Prazosin; Pressoreceptors; Propranolol; Tachycardia | 1988 |
What to expect from the newest drugs.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Antiemetics; Dronabinol; Drug Therapy; Etoposide; Flurbiprofen; Follicle Stimulating Hormone; Humans; Interleukin-2; Ipratropium; Lovastatin; Prazosin; Propanolamines; Streptokinase; Tissue Plasminogen Activator; Tranexamic Acid | 1988 |
Drugs recently released in Belgium. Recombinant DNA yeast-derived hepatitis B vaccine-terazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Hepatitis B Vaccines; Humans; Prazosin; Recombinant Proteins; Viral Hepatitis Vaccines | 1988 |
[Effects of terazosin on the blood pressure responses to tilting in conscious animals: comparison with prazosin].
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Hypotension, Orthostatic; Male; Prazosin; Rabbits; Rats; Rats, Inbred SHR | 1988 |
First European review of terazosin. Proceedings of a symposium. Reykjavik, Iceland, 29th-31st May 1987.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Prazosin | 1987 |
Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha 1-adrenergic and phorbol ester stimulation.
Topics: Adrenergic alpha-Antagonists; Animals; Animals, Newborn; Cells, Cultured; Enzyme Activation; Myocardium; Norepinephrine; Prazosin; Protein Kinase C; Rats; Receptors, Adrenergic, alpha; Tetradecanoylphorbol Acetate | 1988 |
Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Prazosin; Receptors, Adrenergic, beta; Sympathetic Nervous System | 1985 |
Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating.
Topics: Animals; Ascorbic Acid; Cardiomegaly; Cell Division; Cells, Cultured; Cycloheximide; Dopamine; Heart; Muscle Proteins; Myocardial Contraction; Myocardium; Piperazines; Prazosin; Propranolol; Rats; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Sympathomimetics | 1985 |
Role of adrenoceptors and dopamine receptors in modulating left ventricular diastolic function.
Topics: Animals; Diastole; Dobutamine; Dogs; Domperidone; Dopamine; Hemodynamics; Myocardial Contraction; Prazosin; Receptors, Adrenergic; Receptors, Dopamine; Systole; Ventricular Function; Yohimbine | 1988 |
Terazosin kinetics after oral and intravenous doses.
Topics: Administration, Oral; Adolescent; Adult; Chromatography, High Pressure Liquid; Half-Life; Humans; Injections, Intravenous; Kinetics; Male; Piperazines; Prazosin | 1985 |
Effect of clonidine at steady state on blood pressure in spontaneously hypertensive rats. Interaction of various alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Animals; Benzimidazoles; Blood Pressure; Clonidine; Dioxanes; Drug Interactions; Hypertension; Male; Phentolamine; Piperazines; Prazosin; Rats; Rats, Inbred Strains; Yohimbine | 1984 |
Terazosin: intravenous safety evaluation in rats.
Topics: Animals; Antihypertensive Agents; Blepharoptosis; Body Temperature; Body Weight; Dose-Response Relationship, Drug; Eating; Female; Injections, Intravenous; Liver; Male; Piperazines; Prazosin; Rats; Rats, Inbred Strains | 1984 |
Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detection.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Peritoneal Dialysis; Piperazines; Prazosin; Spectrometry, Fluorescence | 1984 |
A new prazosin analogue, Abbott-45975 (A-45975)
Topics: Animals; Antihypertensive Agents; Prazosin; Quinazolines; Rats | 1981 |
Terazosin for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Hypotension, Orthostatic; Male; Prazosin; Prostatic Hyperplasia | 1994 |
Men's health issues.
Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms | 1993 |
Terazosin now indicated for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia | 1994 |
Effect of terazosin on urine storage and voiding in the aging male with prostatism.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Prazosin; Prostatic Hyperplasia; Surveys and Questionnaires; Time Factors; Urinary Bladder; Urination | 1994 |
[Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Time Factors | 1994 |
Terazosin for BPH.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia; Research Design | 1995 |
[Terazosin in the treatment of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Multicenter Studies as Topic; Prazosin; Prostatic Hyperplasia | 1995 |
Hytrin treatment of hypertension and benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia | 1995 |
The medication minute: terazosin.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Patient Education as Topic; Prazosin; Prostatic Hyperplasia | 1995 |
Combination drug therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Drug Synergism; Drug Therapy, Combination; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia | 1995 |
Prejunctional facilitatory alpha 1-adrenoceptors in the rat urinary bladder.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Calcium; Dose-Response Relationship, Drug; Electric Stimulation; Kinetics; Male; Muscle Contraction; Muscle, Smooth; Norepinephrine; Parasympathetic Nervous System; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Urinary Bladder | 1995 |
Luminal dopamine modulates canine ileal water and electrolyte transport.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic alpha-Antagonists; Animals; Biological Transport; Dogs; Dopamine; Electrolytes; Female; Ileum; Intestinal Absorption; Prazosin; Water; Yohimbine | 1995 |
Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate.
Topics: Adrenergic alpha-Antagonists; Animals; Dogs; Dose-Response Relationship, Drug; Epinephrine; Male; Muscle Contraction; Phenoxybenzamine; Prazosin; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Sulfonamides; Tamsulosin | 1993 |
Transurethral resection of the prostate: still the gold standard?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Androstenes; Azasteroids; Catheterization; Finasteride; Humans; Hyperthermia, Induced; Incidence; Male; Middle Aged; Prazosin; Prostatectomy; Prostatic Hyperplasia | 1993 |
[Alpha adrenergic mechanism on the reflex micturition in the male decerebrate dog].
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Decerebrate State; Dogs; Male; Manometry; Midodrine; Prazosin; Reflex; Urethra; Urinary Bladder; Urination; Urodynamics; Yohimbine | 1993 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Diseases; Auscultation; Benzothiadiazines; Cough; Diabetes Mellitus, Type 1; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Minoxidil; Prazosin; Proteinuria; Sodium Chloride Symporter Inhibitors; Verapamil | 1995 |
Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents.
Topics: Adrenergic alpha-Antagonists; Animals; Autonomic Nervous System Diseases; Calcium Channel Blockers; Diltiazem; Disease Models, Animal; Male; Mandelic Acids; Parasympatholytics; Prazosin; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Urinary Bladder, Neurogenic; Urodynamics | 1995 |
Comparison of displacemental potencies of terazosin enantiomers for alpha 1-adrenoceptor subtypes.
Topics: Animals; Aorta; Binding, Competitive; Brain; Cattle; Dogs; In Vitro Techniques; Male; Myocardium; Prazosin; Prostate; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Stereoisomerism | 1994 |
Clinical applications of alpha 1-receptor blockade: terazosin in the management of hypertension. Introduction.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Prazosin; Receptors, Adrenergic, alpha-1 | 1993 |
[Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia].
Topics: Adrenergic alpha-Antagonists; Adult; Enalapril; Female; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1993 |
Prospective evaluation of terazosin for the treatment of autonomic dysreflexia.
Topics: Adrenergic alpha-Agonists; Adult; Autonomic Nervous System Diseases; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Reflex, Abnormal; Severity of Illness Index; Spinal Cord Injuries | 1994 |
Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Follow-Up Studies; Humans; Male; Middle Aged; Penile Erection; Prazosin; Radiography; Reoperation; Spinal Cord Injuries; Television; Urinary Bladder; Urinary Bladder Neck Obstruction; Urodynamics | 1993 |
Hemodynamic effects of terazosin in congestive heart failure.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin | 1993 |
The effect of terazosin on bladder function in the spinal cord injured patient.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Spinal Cord Injuries; Urinary Bladder, Neurogenic; Urinary Incontinence | 1994 |
[The effect of terazosin and nitrendipine on blood insulin, glucose and lipid in SHR rats].
Topics: Adrenergic alpha-Antagonists; Animals; Blood Glucose; Female; Hypertension; Insulin; Lipids; Prazosin; Rats; Rats, Inbred SHR | 1993 |
Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.
Topics: Adrenergic alpha-Antagonists; Affinity Labels; Anesthesia, Endotracheal; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Doxazosin; Male; Models, Biological; Phenylephrine; Piperazines; Prazosin; Pressure; Prostate; Quinazolines; Sulfonamides; Tamsulosin | 1994 |
Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prazosin | 1994 |
Effect of alpha 1-adrenergic blockade on canine ileal water, electrolyte, and glucose absorption.
Topics: Adrenergic alpha-Antagonists; Animals; Dogs; Eating; Electrolytes; Female; Glucose; Ileum; Intestinal Absorption; Prazosin; Receptors, Adrenergic, alpha-1; Water | 1994 |
Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Extracellular Space; Hippocampus; Male; Microdialysis; Neostriatum; Perfusion; Prazosin; Quinazolines; Rats; Rats, Sprague-Dawley; Serotonin | 1994 |
Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies.
Topics: Adrenergic alpha-Antagonists; Calcium; Dose-Response Relationship, Drug; Endothelins; Epithelium; Humans; Immunohistochemistry; In Vitro Techniques; Indomethacin; Isometric Contraction; Male; Muscle, Smooth; Nifedipine; Prazosin; Prostate | 1993 |
Effects of ANG-converting enzyme and alpha 1-adrenoceptor inhibition on intrarenal hemodynamics in SHR.
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Blood Pressure; Drug Interactions; Glomerular Filtration Rate; Hemodynamics; Isoquinolines; Kidney; Kidney Glomerulus; Male; Muscle, Smooth, Vascular; Nephrons; Prazosin; Quinapril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha-1; Regional Blood Flow; Renal Circulation; Species Specificity; Tetrahydroisoquinolines; Vascular Resistance | 1994 |
Administration of terazosin capsules through feeding tubes.
Topics: Adrenergic alpha-Antagonists; Capsules; Enteral Nutrition; Humans; Prazosin | 1995 |
[Pharma-clinics. Drug of the month. Terazosine (Hytrin)].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Hypertension; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 1995 |
Contrast medium induced renal vasoconstriction, role of alpha receptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Contrast Media; Dose-Response Relationship, Drug; Drug Interactions; Phenylephrine; Piperazines; Prazosin; Rabbits; Radiography; Receptors, Adrenergic, alpha-1; Renal Artery; Sulfonamides; Tamsulosin; Vasoconstriction; Vasoconstrictor Agents | 1995 |
Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Female; Humans; Prazosin; Randomized Controlled Trials as Topic; Urination Disorders | 1996 |
Efficacy and safety of terazosin to improve voiding in spinal cord injury patients.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Spinal Cord Injuries; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Bladder, Neurogenic; Urodynamics | 1995 |
Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood.
Topics: Adrenergic alpha-Antagonists; Aging; Animals; Animals, Suckling; Blood Pressure; Drug Administration Schedule; Hypertension; Male; Pilot Projects; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reference Values; Systole | 1996 |
Treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prazosin; Prostatic Hyperplasia | 1996 |
A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anesthesia; Animals; Blood Pressure; Cats; Doxazosin; Heart Rate; Male; Prazosin; Sympathetic Nervous System; Urinary Bladder | 1995 |
alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Clonidine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intraventricular; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Prazosin; Receptors, Opioid; Yohimbine | 1996 |
Study provides head-to-head comparison of terazosin, finasteride.
Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Finasteride; Humans; Male; Oxidoreductases; Prazosin; Prostatic Hyperplasia | 1996 |
Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Female; Humans; Prazosin; Prevalence; Urinary Incontinence | 1996 |
Blockade of alpha-2 adrenergic receptors in the rostral ventrolateral medulla attenuates the sympathoinhibitory response to cocaine.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blood Pressure; Cocaine; Idazoxan; Male; Medulla Oblongata; Microinjections; Piperoxan; Prazosin; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Sympatholytics | 1996 |
Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Hemodynamics; Imidazoles; Infusions, Intravenous; Kidney; Losartan; Male; Obesity; Prazosin; Rats; Rats, Zucker; Renin; Renin-Angiotensin System; Sodium Chloride, Dietary; Sympathetic Nervous System; Tetrazoles | 1996 |
Terazosin, finasteride, or both in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia; Urodynamics | 1997 |
Terazosin, finasteride, or both in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypotension, Orthostatic; Male; Prazosin; Prostatic Hyperplasia | 1997 |
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Doxazosin; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Time Factors; Urethra | 1996 |
Alpha 1-adrenergic blockers: do they have a place in the prophylaxis of migraine?
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Child; Doxazosin; Female; Humans; Male; Middle Aged; Migraine Disorders; Prazosin | 1997 |
[Ureteral jet in patients with benign prostatic hypertrophy: prognostic evaluation during single and combined therapy].
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Ultrasonography, Doppler, Color; Urethra; Urination | 1996 |
Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Animals; Animals, Newborn; Apoptosis; Atrial Natriuretic Factor; Cell Nucleus; Cells, Cultured; Cyclic GMP; Desmin; DNA Fragmentation; Dose-Response Relationship, Drug; Heart; Kinetics; Myeloid Cell Leukemia Sequence 1 Protein; Myocardium; Neoplasm Proteins; Nitroprusside; Norepinephrine; Phosphodiesterase Inhibitors; Polymerase Chain Reaction; Prazosin; Propranolol; Proto-Oncogene Proteins c-bcl-2; Purinones; Rats; Receptors, Atrial Natriuretic Factor | 1997 |
Morphological and pharmacological characterization of guinea-pig prostatic smooth muscle cells in vitro.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Guinea Pigs; Immunohistochemistry; Male; Microscopy, Electron; Muscle Contraction; Muscle, Smooth; Phenylephrine; Prazosin; Prostate | 1997 |
Prostatodynia in United Nations peacekeeping forces in Haiti.
Topics: Abscess; Adrenergic alpha-Antagonists; Adult; Age Factors; Anti-Bacterial Agents; Chronic Disease; Coitus; Diagnosis, Differential; Epididymitis; Genital Diseases, Male; Haiti; Humans; Male; Masturbation; Middle Aged; Military Personnel; Pelvic Pain; Prazosin; Prevalence; Prostatic Diseases; Prostatitis; Retrospective Studies; Scrotum; Stress, Physiological; United Nations; Urinary Calculi; Urinary Tract Infections; Urination Disorders | 1997 |
[3H]R-terazosin binds selectively to alpha1-adrenoceptors over alpha2-adrenoceptors - comparison with racemic [3H]terazosin and [3H]prazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Cricetinae; Humans; Mice; Prazosin; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Stereoisomerism | 1997 |
What is the best medical treatment for benign prostate hyperplasia?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Family Practice; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome | 1997 |
Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Laser Therapy; Male; Microwaves; Middle Aged; Prazosin; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics | 1997 |
Terazosin blockade of nicotine-induced skin flap necrosis in the rat.
Topics: Adrenergic alpha-Antagonists; Animals; Graft Survival; Male; Necrosis; Nicotine; Prazosin; Random Allocation; Rats; Rats, Sprague-Dawley; Surgical Flaps | 1997 |
Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Male; Prazosin; Prostatic Hyperplasia; Urethra | 1997 |
alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Drinking; Ganglionic Blockers; Hypertrophy, Left Ventricular; Male; Myocardium; Nadolol; Prazosin; Rats; Rats, Inbred WKY; Sodium Chloride, Dietary; Weight Gain | 1997 |
Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Enzyme Activation; Heart; Hydralazine; Lipid Peroxidation; Liver; Muscle, Skeletal; Myocardium; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 1997 |
Two district alpha(1)-adrenoceptor subtypes in the human prostate: assessment by radioligand binding assay using 3H-prazosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Binding, Competitive; Dioxanes; Humans; In Vitro Techniques; Kinetics; Male; Nifedipine; Phentolamine; Piperazines; Prazosin; Prostate; Protein Binding; Radioligand Assay; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tritium | 1996 |
Repeated catecholamine surges alter cardiac isomyosin expression but not protein synthesis in the rat heart.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Blood Pressure; Catecholamines; Dobutamine; Female; Heart; Heart Rate; Heart Transplantation; Myocardium; Myosin Heavy Chains; Myosins; Prazosin; Protein Biosynthesis; Rats; Rats, Inbred F344 | 1997 |
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dogs; Humans; Indoles; Isoindoles; Male; Models, Chemical; Prazosin; Prostatic Hyperplasia; Pyrimidinones; Rats; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1997 |
Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Retrospective Studies; Statistics, Nonparametric | 1997 |
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urination | 1997 |
Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography-electrospray mass spectrometry.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Mass Spectrometry; Prazosin; Spectrometry, Fluorescence; Stereoisomerism | 1998 |
Alpha adrenoceptors in the rabbit ear thermoregulatory microcirculation.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Body Temperature Regulation; Ear, External; Imidazoles; Male; Medetomidine; Microcirculation; Models, Cardiovascular; Phenylephrine; Prazosin; Rabbits; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Skin; Vasoconstriction | 1998 |
Effect of cooling on cutaneous microvascular adrenoceptors in vivo in the rabbit ear.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arterioles; Cold Temperature; Dose-Response Relationship, Drug; Ear; Male; Microcirculation; Norepinephrine; Peripheral Nerves; Prazosin; Propranolol; Rabbits; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, beta; Regional Blood Flow; Skin; Vasoconstriction; Venules | 1998 |
Characterization of specific binding of [125I]L-762,459, a selective alpha1A-adrenoceptor radioligand to rat and human tissues.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Amidines; Animals; Binding, Competitive; Cerebral Cortex; Dihydropyridines; Hippocampus; Humans; Iodine Radioisotopes; Kidney; Male; Myocardium; Phentolamine; Piperidines; Prazosin; Prostate; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Vas Deferens | 1998 |
Severe cutaneous reaction due to terazosin.
Topics: Adrenergic alpha-Antagonists; Drug Eruptions; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 1998 |
Determination of terazosin in human plasma, using high-performance liquid chromatography with fluorescence detection.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chromatography, High Pressure Liquid; Fluorescence; Humans; Prazosin; Reproducibility of Results; Sensitivity and Specificity; Time Factors | 1998 |
Alpha-adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amiloride; Animals; Cell Transformation, Viral; Cells, Cultured; Cyclic AMP; Doxazosin; Endothelium, Vascular; Epithelial Sodium Channels; GTP-Binding Proteins; Herpesvirus 4, Human; Humans; Isoproterenol; Membrane Potentials; Norepinephrine; Patch-Clamp Techniques; Prazosin; Rats; Receptors, Adrenergic, alpha; Recombinant Proteins; Second Messenger Systems; Sodium Channels; Thionucleotides; Transcription, Genetic | 1998 |
Prolonged penile erection association with terazosin in a cervical spinal cord injury patient.
Topics: Adrenergic alpha-Antagonists; Adult; Humans; Male; Neck; Prazosin; Priapism; Spinal Cord Injuries; Time Factors; Urinary Bladder, Neurogenic | 1998 |
Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Animals; Male; Prazosin; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tissue Distribution | 1998 |
Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Binding, Competitive; Dogs; Dose-Response Relationship, Drug; Humans; Male; Muscle Contraction; Norepinephrine; Prazosin; Prostate; Rabbits; Rats; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1998 |
Design and synthesis of N-alkylated saccharins as selective alpha-1a adrenergic receptor antagonists.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Alkylation; Animals; Aorta; Cell Line; CHO Cells; Cricetinae; Dogs; Drug Design; Finasteride; Humans; In Vitro Techniques; Male; Models, Chemical; Prazosin; Prostate; Rats; Receptors, Adrenergic, alpha-1; Saccharin; Structure-Activity Relationship; Sulfonamides; Tamsulosin | 1998 |
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 1999 |
Characterization of postjunctional alpha-adrenoceptors in the pithed mouse.
Topics: 3T3 Cells; Adrenergic alpha-Antagonists; Animals; Azepines; Binding, Competitive; Blood Pressure; CHO Cells; Cricetinae; Decerebrate State; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred C57BL; Neuroeffector Junction; Phentolamine; Phenylephrine; Prazosin; Radioligand Assay; Receptors, Adrenergic, alpha; Recombinant Fusion Proteins; Vasoconstrictor Agents; Yohimbine | 1999 |
Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Models, Economic; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Randomized Controlled Trials as Topic | 1999 |
Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Prazosin; Prostatic Neoplasms; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Urination Disorders | 1999 |
By the way, doctor... I'm 78 and have more and more difficulty urinating. I get up three times a night - sometimes more - to go to the bathroom and it takes me a while to start urinating and even longer to stop. I know that this is probably a prostate pro
Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urination Disorders | 1999 |
Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Combined Modality Therapy; Equipment Design; Female; Humans; Middle Aged; Phenoxybenzamine; Prazosin; Proctoscopes; Retrospective Studies; Urinary Bladder Neck Obstruction | 1999 |
Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Brain; Dopamine Agonists; Environment; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mice; Prazosin; Quinolines; Receptors, Adrenergic, alpha; Synaptic Transmission | 1999 |
The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Prazosin; Urinary Bladder Neck Obstruction; Urodynamics | 2000 |
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Drug Prescriptions; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; United States; United States Department of Veterans Affairs | 1999 |
Transdermal drug delivery using electroporation. I. Factors influencing in vitro delivery of terazosin hydrochloride in hairless rats.
Topics: Administration, Cutaneous; Animals; Electroporation; In Vitro Techniques; Prazosin; Rats; Skin | 2000 |
Transdermal drug delivery using electroporation. II. Factors influencing skin reversibility in electroporative delivery of terazosin hydrochloride in hairless rats.
Topics: Administration, Cutaneous; Animals; Electroporation; Hydrogen-Ion Concentration; In Vitro Techniques; Permeability; Prazosin; Rats; Skin | 2000 |
Diet and herbs for BPH?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia | 2000 |
Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Pressure Determination; Dietary Fats; Glomerular Filtration Rate; Heart Rate; Hypertension; Injections, Intravenous; Kidney; Male; Obesity; Phenylephrine; Prazosin; Propranolol; Rabbits; Sodium; Sympathetic Nervous System; Sympathomimetics; Telemetry | 2000 |
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cells, Cultured; Doxazosin; Growth Inhibitors; Humans; Male; Mice; Mice, SCID; Muscle, Smooth; Neoplasm Transplantation; Prazosin; Prostate; Prostatic Neoplasms; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Tamsulosin; Transplantation, Heterologous | 2000 |
Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anticoagulants; Azithromycin; Case-Control Studies; Drug Interactions; Humans; International Normalized Ratio; Male; Middle Aged; Platelet Aggregation Inhibitors; Prazosin; Retrospective Studies; Warfarin | 2000 |
Improved high-performance liquid chromatographic analysis of terazosin in human plasma.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Prazosin; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2000 |
Does induction of apoptosis contribute to the overall clinical profile of terazosin? Introduction.
Topics: Apoptosis; Cell Division; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Stromal Cells | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Division; Doxazosin; Humans; Male; Muscle, Smooth; Prazosin; Prostate; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Stromal Cells; Sulfonamides; Tamsulosin | 2000 |
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Prazosin; Quinazolines; Severity of Illness Index; Sulfonamides; Tamsulosin; Time Factors; Urinary Bladder Neck Obstruction; Urodynamics | 2001 |
Effects of antihypertensive treatment on platelet function in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; beta-Thromboglobulin; Blood Platelets; Blood Pressure; Captopril; Diuretics; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; Reference Values; Trichlormethiazide | 2000 |
Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
Topics: Adrenergic alpha-Antagonists; Aged; Comorbidity; Doxazosin; Humans; Louisiana; Male; Postoperative Complications; Prazosin; Prostatic Hyperplasia; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Transurethral Resection of Prostate; Treatment Failure; Treatment Outcome; Urologic Diseases | 2000 |
Terazosin for vesicosphincter dyssynergia in spinal cord-injured male patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Ataxia; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Spinal Cord Injuries; Time Factors; Urethra; Urologic Diseases | 2000 |
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Antibodies, Monoclonal; Apoptosis; Cell Division; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Linear Models; Male; Prazosin; Prostate; Prostatic Hyperplasia; Receptors, Transforming Growth Factor beta; Regression Analysis; Retrospective Studies; Transforming Growth Factor beta | 2001 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Epilepsy, Tonic-Clonic; Humans; Inclusion Bodies; Levodopa; Mice; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-1; Shy-Drager Syndrome; Syndrome; Synucleins; Tyrosine 3-Monooxygenase | 2001 |
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Chromones; Cricetinae; Dose-Response Relationship, Drug; Doxazosin; Fibroblasts; Inositol Phosphates; Phenethylamines; Prazosin; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tetralones; Tritium | 2001 |
Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prazosin; Predictive Value of Tests; Prostatic Hyperplasia; Treatment Outcome | 2001 |
The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urination; Urodynamics | 2001 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseases; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Morbidity; Netherlands; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Research Design; Risk Factors; Sulfonamides; Tamsulosin | 2001 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Doxazosin; Drug Design; Humans; Indicators and Reagents; Indoles; Isoindoles; L Cells; Male; Mice; Models, Molecular; Molecular Conformation; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Recombinant Proteins; Spleen; Structure-Activity Relationship; Vas Deferens | 2001 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comorbidity; Diabetes Mellitus; Diarrhea; Dizziness; Doxazosin; Drug Therapy, Combination; Fractures, Bone; Heart Diseases; Humans; Hypertension; Hypotension; Male; Neoplasms; Prazosin; Prostatic Hyperplasia; Retrospective Studies; Stroke; Syncope | 2001 |
Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Male; Mesenteric Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Prazosin; Prostate; Receptors, Adrenergic, alpha-1; Renal Artery; Saphenous Vein; Sulfonamides; Tamsulosin; Umbilical Veins | 2001 |
Pharmacological blockade of brain alpha1-adrenoceptors as measured by ex vivo [3H]prazosin binding is correlated with behavioral immobility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Binding, Competitive; Brain; Cerebral Cortex; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intraventricular; Lung; Male; Mice; Prazosin; Receptors, Adrenergic, alpha-1; Tritium | 2001 |
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Endothelial Growth Factors; Factor VIII; Humans; Lymphokines; Male; Middle Aged; Neovascularization, Pathologic; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cholesterol; Humans; Lipoproteins; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Triglycerides | 2001 |
How companies stall generics and keep themselves healthy.
Topics: Drug Industry; Drugs, Generic; Fees, Pharmaceutical; Humans; Patents as Topic; Pharmaceutical Preparations; Prazosin; United States; United States Food and Drug Administration | 2000 |
Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Male; Phenylephrine; Prazosin; Prostate; Pyrimidinones; Regional Blood Flow; Sulfonamides; Tamsulosin; Urethra | 2002 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tumor Cells, Cultured | 2002 |
Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Glomerular Filtration Rate; Hypertension, Renal; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Prazosin; Propranolol; Rats; Rats, Sprague-Dawley; Sodium; Sympathetic Nervous System | 2002 |
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Risk Factors; Sulfonamides; Tamsulosin; Time Factors; Treatment Failure | 2002 |
Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Consciousness; Female; Injections, Intraventricular; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Urinary Bladder Neck Obstruction; Urination | 2002 |
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Japan; Male; Middle Aged; Muscle Contraction; Prazosin; Prostatic Hyperplasia; Quality of Life; Urethra; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination; Urodynamics | 2002 |
Prior iontophoresis of saline enhances vasoconstriction to phenylephrine and clonidine in the skin of the human forearm.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-Agonists; Adult; Clonidine; Female; Forearm; Humans; Iontophoresis; Male; Phenylephrine; Prazosin; Skin; Sodium Chloride; Vasoconstriction; Yohimbine | 2002 |
Impact of alpha1-blockers in men with spinal cord injury and upper tract stasis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Humans; Male; Prazosin; Receptors, Adrenergic, alpha-1; Recovery of Function; Retrospective Studies; Spinal Cord Injuries; Time Factors; Trauma Severity Indices; Treatment Outcome; Urinary Tract; Urodynamics; Urologic Diseases | 2002 |
[Comparison of prazosin, terazosin and tramsulosin: functional and binding studies in isolated prostatic and vascular human tissues].
Topics: Binding Sites; Blood Vessels; Humans; In Vitro Techniques; Male; Prazosin; Prostate; Sulfonamides; Tamsulosin | 2002 |
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
Topics: Adrenergic alpha-Antagonists; alpha-Synuclein; Animals; Body Weight; Brain; Cerebellum; Disease Models, Animal; Female; Inclusion Bodies; Macromolecular Substances; Male; Mice; Mice, Transgenic; Motor Activity; Multiple System Atrophy; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Nitrates; Oligodendroglia; Phosphorylation; Prazosin; Receptors, Adrenergic, alpha-1; Spinal Cord; Survival Rate; Synucleins; Tyrosine; Ubiquitin | 2002 |
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 2002 |
Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade.
Topics: 3T3 Cells; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Calcineurin Inhibitors; Cell Survival; Cells, Cultured; Doxazosin; Heart; Humans; Mice; Myocardium; Piperazines; Prazosin; Rats; Rats, Sprague-Dawley | 2003 |
Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Endothelium, Vascular; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prazosin; Prostatic Neoplasms; Tumor Cells, Cultured | 2003 |
Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Enzyme Inhibitors; Glucose; Heart Rate; Hypertension; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Prazosin; Propranolol; Rats; Rats, Sprague-Dawley; Renin; Sympathetic Nervous System | 2003 |
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anoikis; Cell Adhesion; Cell Survival; Doxazosin; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neoplasm Invasiveness; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Tamsulosin; Transcription Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Chiral separation and preparation of three new antagonists of alpha 1-adrenoceptors by chiral mobile phase HPLC].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Doxazosin; Molecular Structure; Prazosin; Quinazolines | 2002 |
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction | 2003 |
[Hepatotoxicity induced by terazosin].
Topics: Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Humans; Hypertension; Liver; Liver Function Tests; Male; Middle Aged; Prazosin | 2003 |
Role of epinephrine stimulation of CNS alpha1-adrenoceptors in motor activity in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Benzylamines; Betaxolol; Brain; Cell Line; Epinephrine; Humans; Hydrolysis; Imidazoles; Injections, Intraventricular; Kidney; Male; Mice; Motor Activity; Norepinephrine; Phenylephrine; Phosphatidylinositols; Prazosin; Receptors, Adrenergic, alpha; Serotonin | 2003 |
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
Topics: Administration, Intravesical; Adrenergic alpha-Antagonists; Animals; Female; Infusions, Intravenous; Ligation; Piperazines; Prazosin; Purinergic Antagonists; Rats; Rats, Sprague-Dawley; Suramin; Urethral Obstruction; Urinary Bladder Neck Obstruction; Urination; Urination Disorders; Urodynamics | 2003 |
High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Half-Life; Humans; Male; Prazosin | 2001 |
Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Anilides; Animals; Capillaries; Chlormadinone Acetate; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Hormone Antagonists; Male; Microcirculation; Nitriles; Prazosin; Prostate; Rats; Rats, Wistar; Sulfonamides; Tamsulosin; Testosterone; Tosyl Compounds | 2003 |
Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines.
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Division; Cell Line; Humans; Male; Prazosin; Prostatic Neoplasms; Tumor Cells, Cultured | 2003 |
Immobility from administration of the alpha1-adrenergic antagonist, terazosin, in the IVth ventricle in rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Interactions; Environment; Immobilization; Injections, Intraventricular; Male; Motor Activity; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |
Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.
Topics: Chromatography, High Pressure Liquid; Doxazosin; Prazosin; Reproducibility of Results; Stress, Mechanical | 2004 |
Measurement of low-dose active pharmaceutical ingredient in a pharmaceutical blend using frequency-domain photon migration.
Topics: Calibration; Dose-Response Relationship, Drug; Pharmaceutical Preparations; Photons; Prazosin; Technology, Pharmaceutical | 2004 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
[Effect of nitric oxide donor and alpha1-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro].
Topics: Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; Humans; In Situ Nick-End Labeling; Male; Nitric Oxide Donors; Prazosin; Prostatic Hyperplasia; Stromal Cells | 2004 |
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Cells, Cultured; Doxazosin; Electric Stimulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Prazosin; Xenopus | 2004 |
Sympathetic influence on capsaicin-evoked enhancement of dorsal root reflexes in rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Capsaicin; Electric Stimulation; Electrodes; Extracellular Space; Male; Membrane Potentials; Nerve Fibers; Nerve Fibers, Myelinated; Nerve Fibers, Unmyelinated; Neural Conduction; Norepinephrine; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic; Reflex; Spinal Nerve Roots; Sympathectomy; Sympathetic Nervous System; Yohimbine | 2004 |
Gross mapping of alpha1-adrenoceptors that regulate behavioral activation in the mouse brain.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Drug Interactions; Immobilization; Male; Mice; Microinjections; Motor Activity; Norepinephrine; Prazosin; Receptors, Adrenergic, alpha-1 | 2004 |
Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia?
Topics: Antineoplastic Agents; Catheter Ablation; Finasteride; Humans; Male; Meta-Analysis as Topic; Prazosin; Prostatic Hyperplasia | 2004 |
[The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Male; Phenoxybenzamine; Prazosin; Prostatic Neoplasms; Quinazolines | 2004 |
Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice.
Topics: Angiotensins; Animals; Atenolol; Blood Pressure; Heart Rate; Housing, Animal; Hypertension; Male; Mice; Mice, Inbred C57BL; Motor Activity; Prazosin; Stress, Psychological; Sympathetic Nervous System | 2004 |
Sympathetic modulation of activity in Adelta- and C-primary nociceptive afferents after intradermal injection of capsaicin in rats.
Topics: Action Potentials; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Capsaicin; Carbolines; Injections, Intradermal; Male; Nerve Fibers, Myelinated; Nerve Fibers, Unmyelinated; Neurons, Afferent; Nociceptors; Physical Stimulation; Prazosin; Rats; Rats, Sprague-Dawley; Sympathectomy; Vasoconstrictor Agents; Vasopressins; Yohimbine | 2005 |
Role of locus coeruleus alpha1-adrenoceptors in motor activity in rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Autoradiography; Behavior, Animal; Benzylamines; Dose-Response Relationship, Drug; Drug Interactions; Exploratory Behavior; Immobilization; Locus Coeruleus; Male; Medial Forebrain Bundle; Motor Activity; Neurotransmitter Uptake Inhibitors; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1 | 2004 |
Visceral afferent bias on cortical processing: role of adrenergic afferents to the basal forebrain cholinergic system.
Topics: Adrenergic alpha-Antagonists; Animals; Brain Stem; Cholinergic Fibers; Drug Interactions; Electroencephalography; Epinephrine; Evoked Potentials, Auditory; Male; Norepinephrine; Prazosin; Prosencephalon; Rats; Rats, Sprague-Dawley; Visceral Afferents | 2004 |
Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Cardiovascular Physiological Phenomena; Dogs; Heart Rate; Male; Phenylephrine; Prazosin; Stroke Volume; Ventricular Function, Left | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Probability; Prostatic Hyperplasia; Quinazolines; Reference Values; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Drug Therapy; Female; Furosemide; Health Services for the Aged; Hospitals, Veterans; Humans; Hydrochlorothiazide; Hypotension, Orthostatic; Lisinopril; Male; Outpatients; Patient Selection; Prazosin; Prevalence; Retrospective Studies; Veterans | 2005 |
Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Humans; In Situ Nick-End Labeling; Keratins; Male; Middle Aged; Neovascularization, Pathologic; Prazosin; Urinary Bladder Neoplasms | 2005 |
Evidence of roles of central alpha1-adrenoceptors and epinephrine in orexin A-induced hyperactivity in mice.
Topics: Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Epinephrine; Hyperkinesis; Imidazoles; Injections, Intraventricular; Intracellular Signaling Peptides and Proteins; Male; Neuropeptides; Orexin Receptors; Orexins; Prazosin; Rats; Receptors, Adrenergic; Receptors, G-Protein-Coupled; Receptors, Neuropeptide | 2005 |
Baroreceptor mediated blood pressure regulation is not affected during dose dependent inhibition of prostatic contractions by terazosin.
Topics: Animals; Baroreflex; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Male; Muscle Contraction; Phenylephrine; Prazosin; Pressoreceptors; Prostate; Prostatic Hyperplasia | 2004 |
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Chronic Disease; Humans; Male; Pelvic Pain; Prazosin; Prostatitis; Syndrome; Time Factors | 2005 |
The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Anticoagulants; Azithromycin; Cohort Studies; Drug Interactions; Female; Humans; International Normalized Ratio; Levofloxacin; Male; Ofloxacin; Platelet Aggregation Inhibitors; Prazosin; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Warfarin | 2005 |
Alpha(1)-adrenergic and alpha(2)-adrenergic balance in the dorsal pons and gross behavioral activity of mice in a novel environment.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Animals; Behavior, Animal; Dexmedetomidine; Dose-Response Relationship, Drug; Environment; Imidazoles; Male; Mice; Motor Activity; Pons; Prazosin; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2 | 2005 |
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Phacoemulsification; Prazosin; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2005 |
Terazosin in the treatment of premature ejaculation: a short-term follow-up.
Topics: Adrenergic alpha-Antagonists; Adult; Ejaculation; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin | 2005 |
Role of CNS alpha1-adrenoceptor activity in central fos responses to novelty.
Topics: Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Brain Chemistry; Central Nervous System; Dialysis; Exploratory Behavior; Idazoxan; Immunohistochemistry; Male; Oncogene Proteins v-fos; Phenylephrine; Prazosin; Protein Binding; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1 | 2006 |
Effects of different alpha-1 adrenoceptor blockers on proximal urethral function using in vivo isovolumetric pressure changes.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cardiovascular System; Male; Phenylephrine; Prazosin; Quinazolines; Rabbits; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Urethra | 2005 |
In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Doxazosin; Male; Prazosin; Pupil; Quinazolines; Rabbits; Receptors, Adrenergic, alpha-1; Time Factors; Urethra | 2006 |
Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride.
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Computer Simulation; Crystallography, X-Ray; Drug Stability; Humidity; Magnetic Resonance Spectroscopy; Methanol; Models, Molecular; Molecular Structure; Phase Transition; Prazosin; Solvents; Water | 2006 |
alpha-blocker treatment of urolithiasis.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Glucocorticoids; Humans; Prazosin; Sulfonamides; Tamsulosin; Urolithiasis | 2006 |
alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Regression Analysis; Treatment Outcome; Urination Disorders; Urodynamics | 2006 |
Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Polyuria; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urination Disorders; Urodynamics | 2006 |
Role of alpha(1)-adrenoceptors of the locus coeruleus in self-stimulation of the medial forebrain bundle.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Locus Coeruleus; Male; Medial Forebrain Bundle; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Self Administration | 2007 |
Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate.
Topics: Adrenergic alpha-Antagonists; Animals; Glycosaminoglycans; Male; Matrix Metalloproteinase 2; Prazosin; Prostate; Rats; Rats, Wistar | 2007 |
Endogenous excitatory drive modulating respiratory muscle activity across sleep-wake states.
Topics: Adrenergic alpha-Antagonists; Animals; Hypoglossal Nerve; Male; Microdialysis; Motor Neurons; Prazosin; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT2; Respiratory Muscles; Sleep Apnea Syndromes; Sleep Stages; Sleep, REM; Wakefulness | 2006 |
Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Topics: Adrenergic alpha-Antagonists; Aged; Bangladesh; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome | 2005 |
Cardio-protective role of terazosin is possibly mediated through alteration in thyroid function.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Glucose; Cholesterol, Dietary; Disease Models, Animal; Eating; Female; Glycogen; Heart; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Lipid Peroxidation; Lipids; Lipoproteins; Liver; Prazosin; Rats; Rats, Wistar; Thyroid Gland; Thyroxine; Triiodothyronine | 2006 |
Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Dexamethasone; Drug Interactions; Male; Membrane Proteins; Microsomes, Liver; Prazosin; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Troleandomycin | 2007 |
New-onset priapism associated with ingestion of terazosin in an otherwise healthy man.
Topics: Adrenergic alpha-Antagonists; Adult; Health Status; Humans; Male; Prazosin; Priapism; Urinary Bladder Diseases | 2007 |
The effects of systemic alpha-1 adrenergic antagonists on pupil diameter in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Doxazosin; Iris; Male; Prazosin; Pupil; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin | 2007 |
Determination of adenosine effects and adenosine receptors in murine corpus cavernosum.
Topics: 2-Chloroadenosine; Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Atropine; Bretylium Tosylate; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Penile Erection; Phenylephrine; Prazosin; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptors, Purinergic P1; Triazoles | 2007 |
A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Humans; Levofloxacin; Male; Ofloxacin; Prazosin; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Specimen Handling; Spectrometry, Fluorescence; Therapeutic Equivalency | 2007 |
Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Animals; Humans; Indoles; Male; Prazosin; Prostate; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2007 |
Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia; Pyridines; Quality of Life; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics; Zolpidem | 2007 |
Comparison of cystometric methods in female rats.
Topics: Adrenergic alpha-Antagonists; Anesthesia, General; Animals; Female; Prazosin; Pressure; Rats; Rats, Sprague-Dawley; Sensation; Ureteral Obstruction; Urinary Bladder; Urinary Catheterization; Urination; Urodynamics | 2008 |
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Doxazosin; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prazosin; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2007 |
Human epididymal and prostatic tracts of vas deferens: different contraction response to noradrenaline stimulation in isolated organ bath assay.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Aged; Dose-Response Relationship, Drug; Doxazosin; Epididymis; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Norepinephrine; Organ Specificity; Prazosin; Prostate; Quinazolines; Stimulation, Chemical; Vas Deferens | 2007 |
Effect of peripheral sympathetic nerve dysfunction on salt sensitivity of arterial pressure.
Topics: Animals; Antihypertensive Agents; Autonomic Nervous System Diseases; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Rate; Hexamethonium; Hypertension; Male; Phenylephrine; Prazosin; Rats; Sodium Chloride | 2008 |
Lichenoid drug eruption to terazosin.
Topics: Adrenergic alpha-Antagonists; Aged, 80 and over; Drug Eruptions; Humans; Lichenoid Eruptions; Male; Prazosin; Prostatic Hyperplasia | 2008 |
alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice.
Topics: Acetaminophen; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Catecholamines; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Doxazosin; Erythrocytes; Gene Expression Regulation, Enzymologic; Glutamate-Cysteine Ligase; Glutathione; Heme Oxygenase-1; Liver; Liver Circulation; Liver Diseases; Male; Membrane Proteins; Mice; Prazosin; Protein Binding; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Time Factors; Transaminases | 2008 |
Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Treatment Outcome | 2008 |
Acute intoxication with terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Bradycardia; Drug Overdose; Electrocardiography; Humans; Male; Prazosin; Prostatic Hyperplasia; Suicide, Attempted | 2008 |
Delayed effects of hypotensive drugs on structural characteristics of the renal glomerular system in hypertensive NISAG rats.
Topics: Animals; Antihypertensive Agents; Enalapril; Hypertension; Kidney Glomerulus; Losartan; Male; Nifedipine; Prazosin; Rats; Time Factors | 2007 |
Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Agouti-Related Protein; Animals; Antihypertensive Agents; Blood Pressure; Eating; Female; Heart Rate; Hypertension, Renal; Hypothalamus; Male; Melanocortins; Melanocyte-Stimulating Hormones; Neuropeptide Y; Prazosin; Pro-Opiomelanocortin; Propranolol; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Melanocortin, Type 3; Receptor, Melanocortin, Type 4; Receptors, Leptin; RNA, Messenger; Sympathetic Nervous System | 2008 |
Combined use of melatonin and terazosin restores bladder contractility in rabbits with partial outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Drug Therapy, Combination; Humans; Melatonin; Muscle Contraction; Oxidative Stress; Prazosin; Rabbits; Treatment Outcome; Urethral Obstruction; Urinary Bladder | 2008 |
Acute generalized exanthematous pustulosis caused by terazosin hydrochloride.
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Aged; Drug Eruptions; Exanthema; Humans; Male; Prazosin; Skin Diseases, Vesiculobullous | 2008 |
Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Duloxetine Hydrochloride; Female; Idazoxan; Methiothepin; Prazosin; Pressure; Rats; Rats, Sprague-Dawley; Reflex; Selective Serotonin Reuptake Inhibitors; Sneezing; Thiophenes; Urethra; Urinary Incontinence, Stress; Vagina | 2008 |
alpha(1)-Adrenoceptors augment thermal hyperalgesia in mildly burnt skin.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Burns; Clonidine; Female; Hot Temperature; Humans; Hyperalgesia; Iontophoresis; Male; Nociceptors; Norepinephrine; Phenylephrine; Prazosin; Receptors, Adrenergic, alpha-1; Sensory Receptor Cells; Skin; Yohimbine; Young Adult | 2009 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Middle Aged; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Retrospective Studies; Sulfonamides; Tamsulosin; Treatment Outcome | 2008 |
Noradrenaline triggers muscle tone by amplifying glutamate-driven excitation of somatic motoneurones in anaesthetized rats.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anesthesia; Animals; Electromyography; Isoproterenol; Male; Masseter Muscle; Motor Neurons; Muscle Tonus; Norepinephrine; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, beta; Receptors, AMPA; Receptors, Glutamate; Trigeminal Nuclei; Vasoconstrictor Agents | 2008 |
Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Genistein; Humans; In Situ Nick-End Labeling; Male; Microscopy, Fluorescence; Prazosin; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2009 |
Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Male; Nocturia; Pilot Projects; Prazosin; Prospective Studies; Prostatism | 2009 |
Terazosin treatment suppresses basic fibroblast growth factor expression in the rat ventral prostate.
Topics: Adrenergic alpha-Antagonists; Animals; Blotting, Western; Fibroblast Growth Factor 2; Immunohistochemistry; Male; Prazosin; Prostate; Rats; Rats, Wistar | 2009 |
Fabrication of terazocin-loaded poly(D,L-lactide) microspheres by an ultrasonic spray drying method and their release behaviors.
Topics: Microscopy, Electron, Scanning; Polyesters; Prazosin; Spectroscopy, Fourier Transform Infrared; Ultrasonics | 2008 |
A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results.
Topics: Acetamides; Adrenergic alpha-Antagonists; Aged; Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; Cresols; Epidemiologic Methods; Humans; Hypnotics and Sedatives; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Prazosin; Prostatic Hyperplasia; Pyrimidines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Functional screening of adrenergic receptors by measuring intracellular calcium using the FlexStation scanning fluorimeter.
Topics: Animals; Biotechnology; Calcium; Cell Line; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorometry; GTP-Binding Proteins; Humans; Kinetics; Prazosin; Protein Binding; Quinazolines; Receptors, Adrenergic; Signal Transduction; Sulfonamides; Tamsulosin | 2009 |
Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Sectional Studies; Eye Color; Glaucoma; Humans; Intraoperative Complications; Iris; Iris Diseases; Male; Muscle, Smooth; Ocular Hypertension; Prazosin; Prospective Studies; Prostatic Hyperplasia; Pupil; Sulfonamides; Syndrome; Tamsulosin; Tomography, Optical Coherence | 2009 |
Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Calcium Channel Blockers; Drug Therapy, Combination; Female; Male; Prazosin; Prostatic Hyperplasia; Prostatism; Rats; Rats, Sprague-Dawley; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Direct high-performance liquid chromatography enantioseparation of terazosin on an immobilised polysaccharide-based chiral stationary phase under polar organic and reversed-phase conditions.
Topics: Chromatography, High Pressure Liquid; Drug Contamination; Linear Models; Prazosin; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2009 |
Alpha-1 adrenoceptor stimulation triggers axon-reflex vasodilatation in human skin.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Axons; Blood Vessels; Female; Humans; Inflammation; Laser-Doppler Flowmetry; Male; Methoxamine; Middle Aged; Prazosin; Receptors, Adrenergic, alpha-1; Reflex; Regional Blood Flow; Skin; Sympathetic Fibers, Postganglionic; Vasodilation; Young Adult | 2009 |
Buthus tamulus venom-induced vasosensory reflexes are mediated through efferent pathways in sympathetic and vagal parasympathetics.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Blood Pressure; Efferent Pathways; Electrocardiography; Heart Rate; Injections, Intra-Arterial; Male; Prazosin; Rats; Reflex; Respiratory Mechanics; Scorpion Venoms; Sympathetic Nervous System; Vagus Nerve | 2009 |
Fluorescent quantification of terazosin hydrochloride content in human plasma and tablets using second-order calibration based on both parallel factor analysis and alternating penalty trilinear decomposition.
Topics: Adrenergic alpha-Antagonists; Algorithms; Calibration; Chromatography, High Pressure Liquid; Factor Analysis, Statistical; Fluorescent Dyes; Humans; Prazosin; Spectrometry, Fluorescence; Tablets | 2009 |
Role of alpha adrenergic blocker in the management of posterior urethral valves.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Child, Preschool; Cystoscopy; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Infant; Infant, Newborn; Prazosin; Retrospective Studies; Time Factors; Treatment Outcome; Urethra; Urinary Bladder Neck Obstruction; Urodynamics | 2009 |
Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cricetinae; Doxazosin; Indoles; Male; Mesocricetus; Mice; Mice, Inbred ICR; Muscle Contraction; Norepinephrine; Prazosin; Quinazolines; Ureter | 2009 |
Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
Topics: Adrenergic alpha-Antagonists; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Daunorubicin; Digoxin; Doxazosin; Drug Resistance, Multiple; HeLa Cells; Humans; Neoplasm Proteins; Prazosin; Vinblastine | 2009 |
Development and validation of an Arabic version of the International Prostate Symptom Score.
Topics: Adrenergic alpha-Antagonists; Humans; Language; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Reproducibility of Results; ROC Curve; Surveys and Questionnaires; United Arab Emirates | 2010 |
A round table discussion: case studies of patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Adult; Cystoscopy; Humans; Male; Medical Records; Middle Aged; Prazosin; Prostatism; Transurethral Resection of Prostate; Urinary Bladder Diseases; Urodynamics | 2009 |
Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Female; Humans; Male; Prazosin; Sulfonamides; Tamsulosin; Time Factors; Urinary Bladder Neck Obstruction; Urination Disorders | 2010 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin | 2010 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Metoprolol; Neoplasms; Norepinephrine; Odds Ratio; Prazosin; Propranolol; Prostatic Neoplasms; Risk Assessment | 2011 |
A pharma-robust design method to investigate the effect of PEG and PEO on matrix tablets.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Diffusion; Drug Compounding; Gels; Kinetics; Models, Chemical; Models, Statistical; Polyethylene Glycols; Prazosin; Solubility; Tablets; Technology, Pharmaceutical; Water | 2010 |
Ventral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Amphetamine; Animals; Basal Ganglia; Drug Interactions; Inhibition, Psychological; Male; Microinjections; Motor Activity; Nucleus Accumbens; Prazosin; Rats; Rats, Sprague-Dawley; Reflex, Startle; Sensory Gating; Timolol | 2010 |
Antagonism of lateral amygdala alpha1-adrenergic receptors facilitates fear conditioning and long-term potentiation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Amygdala; Animals; Conditioning, Psychological; Cues; Electric Stimulation; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; Fear; In Vitro Techniques; Injections; Injections, Intraperitoneal; Long-Term Potentiation; Male; Neurons; Patch-Clamp Techniques; Prazosin; Rats; Rats, Sprague-Dawley; Stimulation, Chemical | 2010 |
Identification of a novel form of noradrenergic-dependent respiratory motor plasticity triggered by vagal feedback.
Topics: Adrenergic alpha-1 Receptor Antagonists; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Apnea; Diaphragm; Feedback, Sensory; Hypoglossal Nerve; Hypoxia; Ketanserin; Long-Term Potentiation; Male; Motor Neurons; Prazosin; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, AMPA; Respiratory System; Serotonin Antagonists; Vagus Nerve | 2010 |
Time-oriented experimental design method to optimize hydrophilic matrix formulations with gelation kinetics and drug release profiles.
Topics: Delayed-Action Preparations; Excipients; Gels; Models, Statistical; Prazosin; Stearic Acids; Tablets; Time Factors | 2011 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; Endothelial Cells; Endothelium, Vascular; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography | 2011 |
A novel three-layered tablet for extended release with various layer formulations and in vitro release profiles.
Topics: Adrenergic alpha-1 Receptor Antagonists; Delayed-Action Preparations; Drug Delivery Systems; Excipients; Hydrophobic and Hydrophilic Interactions; Kinetics; Polymers; Prazosin; Solubility; Tablets; Viscosity | 2011 |
Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions.
Topics: Adrenergic alpha-1 Receptor Antagonists; Binding, Competitive; Cell Line; Cell Membrane; Chromatography; Doxazosin; Humans; Methods; Phentolamine; Piperazines; Prazosin; Protein Binding; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2011 |
Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cohort Studies; Doxazosin; Drug Combinations; Humans; Intraoperative Complications; Iris Diseases; Male; Muscle, Smooth; Mydriatics; Phacoemulsification; Phenylephrine; Prazosin; Predictive Value of Tests; Prospective Studies; Pupil; Risk Factors; Sensitivity and Specificity; Sulfonamides; Syndrome; Tamsulosin; Tropicamide | 2011 |
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2012 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Family Practice; Humans; Indoles; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2012 |
Cocaine self-administration is not dependent upon mesocortical α1 noradrenergic signaling.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Benzazepines; Cocaine; Conditioning, Operant; Dopamine; Dopamine Antagonists; Male; Norepinephrine; Prazosin; Prefrontal Cortex; Rats; Reinforcement, Psychology; Reward; Self Administration; Ventral Tegmental Area | 2012 |
A new experimental design method to optimize formulations focusing on a lubricant for hydrophilic matrix tablets.
Topics: Adrenergic alpha-1 Receptor Antagonists; Chemistry, Pharmaceutical; Excipients; Gels; Hydrophobic and Hydrophilic Interactions; Kinetics; Lubricants; Models, Chemical; Prazosin; Research Design; Solubility; Statistics as Topic; Stearic Acids; Tablets; Water | 2012 |
Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Allosteric Regulation; Animals; Arrestins; beta-Arrestins; Chemokines; CHO Cells; Cricetinae; HEK293 Cells; Humans; Inositol Phosphates; Labetalol; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Prazosin; Prostate; Protein Structure, Quaternary; Receptors, Adrenergic, alpha-1; Receptors, G-Protein-Coupled; Receptors, Interleukin-8B | 2012 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Cerebral Infarction; Diabetes Mellitus, Type 2; Diffusion Magnetic Resonance Imaging; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Famotidine; Humans; Hypertension; Hypoglycemic Agents; Labetalol; Male; Metformin; Middle Aged; Nifedipine; Peptic Ulcer; Prazosin; Sulfonylurea Compounds | 2012 |
Terazosin-induced alterations in catalase expression and lipid peroxidation in the rat seminal vesicles.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Catalase; Fertility; Lipid Peroxidation; Male; Prazosin; Rats; Rats, Wistar; Seminal Vesicles | 2013 |
Structural characteristics of renal glomerular system in ISIAH rats under conditions of chronic stress and preventive hypotensive drug therapy.
Topics: Animals; Antihypertensive Agents; Enalapril; Kidney Glomerulus; Losartan; Male; Prazosin; Rats; Stress, Physiological | 2011 |
Effect of global and regional sympathetic blockade on arterial pressure during water deprivation in conscious rats.
Topics: Adrenal Cortex; Adrenalectomy; Adrenergic alpha-1 Receptor Antagonists; Animals; Behavior, Animal; Blood Pressure; Consciousness; Heart Rate; Kidney; Male; Osmolar Concentration; Prazosin; Rats; Rats, Sprague-Dawley; Sympathectomy; Sympathetic Nervous System; Sympatholytics; Water Deprivation | 2012 |
An alpha1-adrenoceptor blocker terazosin improves urine storage function in the spinal cord in spinal cord injured rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Female; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Spinal Cord; Spinal Cord Injuries; Urinary Bladder; Urination | 2013 |
Antidepressant-induced excessive sweating: clinical features and treatment with terazosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Antidepressive Agents; Female; Humans; Hyperhidrosis; Male; Middle Aged; Prazosin; Treatment Outcome; Young Adult | 2013 |
On the role of noradrenergic system in PTSD and related sleep disturbances. The use of terazosin in PTSD related nightmares: a case report.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Neurons; Adult; Dreams; Female; Humans; Prazosin; Sleep Wake Disorders; Stress Disorders, Post-Traumatic | 2013 |
Comparison of terazosin and prazosin for treatment of vesico-urethral reflex dyssynergia in dogs.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Dog Diseases; Dogs; Male; Prazosin; Treatment Outcome; Urinary Bladder; Urinary Retention; Urological Agents | 2013 |
Rapid and sensitive online determination of some selective α1-blockers by flow injection analysis with micelle-enhanced fluorescence detection.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Flow Injection Analysis; Fluorescence; Internet; Micelles; Prazosin; Quinazolines; Spectrometry, Fluorescence; Time Factors | 2013 |
[Central retinal vein occlusion associated with severe bilateral carotid stenosis].
Topics: Adrenergic alpha-1 Receptor Antagonists; Anticoagulants; Carotid Stenosis; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prazosin; Prognosis; Retinal Vein Occlusion; Risk Factors; Severity of Illness Index; Treatment Outcome; Ultrasonography | 2013 |
[The effects and its mechanism of N-arginine chitosan as transdermal enhancer].
Topics: Administration, Cutaneous; Animals; Arginine; Aspirin; Cell Line; Cell Survival; Cell-Penetrating Peptides; Chitosan; Drug Carriers; Humans; Isosorbide Dinitrate; Keratinocytes; Male; Mice; Prazosin; Skin Absorption | 2013 |
Terazosin activates Pgk1 and Hsp90 to promote stress resistance.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Cells, Cultured; Cytokines; HSP90 Heat-Shock Proteins; Infarction, Middle Cerebral Artery; Mice; Models, Molecular; Phosphoglycerate Kinase; Prazosin; Protein Conformation; Rats; Sepsis; Stress, Physiological; Stroke | 2015 |
Rayleigh light scattering detection of three α1-adrenoceptor antagonists coupled with high performance liquid chromatograph.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Dimerization; Doxazosin; Dynamic Light Scattering; Humans; Hydrogen Bonding; Limit of Detection; Models, Molecular; Prazosin | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
The stress of maternal separation causes misprogramming in the postnatal maturation of rat resistance arteries.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Animals; Animals, Newborn; Blood Pressure; Gene Expression Regulation, Developmental; Maternal Deprivation; Mesenteric Arteries; Muscle Proteins; Muscle, Smooth, Vascular; Myosin Heavy Chains; Myosin-Light-Chain Kinase; Phenylephrine; Phosphoproteins; Prazosin; Protein Phosphatase 1; Rats; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stress, Psychological; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2015 |
[ASSESSMENT OF EFFICIENCY OF TREATMENT OF OVERACTIVE BLADDER IN ELDERLY PATIENTS].
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Prazosin; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2015 |
Noradrenergic Mechanisms Controlling Urethral Smooth and Striated Muscle Function in Urethral Continence Reflex in Rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic Neurons; Animals; Benzamidines; Bungarotoxins; Female; Fluoxetine; Medetomidine; Muscle, Smooth; Muscle, Striated; Norepinephrine; Prazosin; Rats; Rats, Sprague-Dawley; Reflex; Urethra | 2015 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Doxazosin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides; Tamsulosin | 2016 |
Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison.
Topics: Adrenergic alpha-Antagonists; Humans; Pain Measurement; Pain, Postoperative; Prazosin; Quinazolines; Stents; Treatment Outcome; Ureteral Obstruction | 2016 |
Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/
Topics: Humans; Levofloxacin; Male; Pelvic Pain; Prazosin; Prostatitis | 2017 |
Myocardial infarction induced by oral terazosin in a patient with predisposing structural cardiomyopathy: case report.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angina Pectoris; Cardiomyopathies; Coronary Angiography; Echocardiography, Doppler; Humans; Male; Myocardial Infarction; Prazosin; Syncope; Ventricular Outflow Obstruction | 2016 |
Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Competence; Fellowships and Scholarships; Female; Finasteride; Health Knowledge, Attitudes, Practice; Humans; Internship and Residency; Intraoperative Complications; Iris Diseases; Male; Medical Staff, Hospital; Ophthalmology; Patient Education as Topic; Prazosin; Prostatic Hyperplasia; Referral and Consultation; Sulfonamides; Surveys and Questionnaires; Syndrome; Tamsulosin; Urological Agents; Urology; Vision Disorders | 2016 |
Alpha adrenergic receptor blockade increases capillarization and fractional O
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Hemodynamics; Humans; Male; Muscle, Skeletal; Neovascularization, Physiologic; Oxygen Consumption; Prazosin; Regional Blood Flow | 2017 |
Pharmacological Analysis of the Therapeutic Effect of Radioprotectors Cystamine and Indralin in the Capacity of Radiomitigators.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cystamine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Gamma Rays; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Phenols; Prazosin; Radiation Injuries, Experimental; Radiation-Protective Agents; Rats; Receptors, Adrenergic, alpha-1; Receptors, Serotonin, 5-HT2; Reserpine; Whole-Body Irradiation | 2017 |
Utility of Hantzsch reaction for development of highly sensitive spectrofluorimetric method for determination of alfuzosin and terazosin in bulk, dosage forms and human plasma.
Topics: Adrenergic alpha-1 Receptor Antagonists; Dosage Forms; Humans; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence | 2017 |
Norepinephrine regulates cocaine-primed reinstatement via α1-adrenergic receptors in the medial prefrontal cortex.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Dopamine Uptake Inhibitors; Enzyme Inhibitors; Extinction, Psychological; Food; Male; Norepinephrine; Nucleus Accumbens; Prazosin; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Reinforcement Schedule; Self Administration; Ventral Tegmental Area | 2017 |
Palladium nanoparticles in electrochemical sensing of trace terazosin in human serum and pharmaceutical preparations.
Topics: Electrochemical Techniques; Humans; Metal Nanoparticles; Palladium; Prazosin | 2017 |
Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy.
Topics: Adenosine Triphosphate; Animals; Axons; Disease Models, Animal; Disease Susceptibility; Energy Metabolism; Gene Expression Regulation, Developmental; Humans; Mice; Mitochondria; Motor Neurons; Muscle, Skeletal; Muscular Atrophy, Spinal; Phosphoglycerate Kinase; Prazosin; Spinal Cord; Survival of Motor Neuron 1 Protein; Zebrafish | 2017 |
Noradrenergic signaling in the VTA modulates cocaine craving.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Cocaine; Conditioning, Operant; Craving; Dopamine Uptake Inhibitors; Drug-Seeking Behavior; Idazoxan; Male; Phenylephrine; Prazosin; Propranolol; Rats; Rats, Sprague-Dawley; Self Administration; Ventral Tegmental Area | 2018 |
Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors.
Topics: Animals; Apoptosis; Cell Survival; Databases, Chemical; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Docking Simulation; PC12 Cells; Phosphoglycerate Kinase; Prazosin; Protein Kinase Inhibitors; Rats; Small Molecule Libraries | 2017 |
An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
Topics: Doxazosin; Fluorescence; Humans; Limit of Detection; o-Phthalaldehyde; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence | 2018 |
Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Doxazosin; Fluorescence; Humans; Limit of Detection; Micelles; Pharmaceutical Preparations; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence; Tablets | 2018 |
A novel electrochemical sensor based on electrode modified with gold nanoparticles and molecularly imprinted polymer for rapid determination of trazosin.
Topics: Catalysis; Electrochemical Techniques; Electrodes; Gold; Humans; Hydrogen-Ion Concentration; Male; Metal Nanoparticles; Molecular Imprinting; Oxidation-Reduction; Polymers; Prazosin; Reproducibility of Results; Tablets; Time Factors | 2018 |
Adrenergic receptor blockade attenuates placental ischemia-induced hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Female; Ischemia; Placenta; Prazosin; Pre-Eclampsia; Pregnancy; Propranolol; Rats; Rats, Wistar | 2018 |
Terazosin or baclofen in young men with chronic orchialgia: A cohort study of 499 patients.
Topics: Adolescent; Adult; Baclofen; Chronic Pain; Cohort Studies; Humans; Male; Prazosin; Testis; Treatment Outcome; Young Adult | 2020 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Drosophila melanogaster; Female; Glycolysis; Humans; Induced Pluripotent Stem Cells; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Phosphoglycerate Kinase; Prazosin; Rats | 2019 |
Magnetic-Dispersive Solid Phase Extraction Based on Graphene Oxide-Fe3O4 Nanocomposites Followed by High Performance Liquid Chromatography-Fluorescence for the Preconcentration and Determination of Terazosin Hydrochloride in Human Plasma.
Topics: Chromatography, High Pressure Liquid; Ferrosoferric Oxide; Graphite; Humans; Magnetics; Plasma; Prazosin; Solid Phase Extraction | 2020 |
Postorgasmic illness syndrome: potential new treatment options for a rare disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Humans; Male; Orgasm; Prazosin; Quinazolines; Sexual Dysfunction, Physiological; Syndrome | 2020 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Syncope; Tamsulosin | 2019 |
Does α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Eccrine Glands; Endurance Training; Exercise; Humans; Male; Prazosin; Receptors, Adrenergic, alpha-1; Skin Temperature; Sweating; Young Adult | 2020 |
Determination of terazosin in the presence of prazosin: Different state-of-the-art machine learning algorithms with UV spectroscopy.
Topics: Algorithms; Bayes Theorem; Counterfeit Drugs; Green Chemistry Technology; Machine Learning; Neural Networks, Computer; Prazosin; Spectrophotometry, Ultraviolet; Tablets | 2020 |
Updating the European Pharmacopoeia impurity profiling method for terazosin and suggesting alternative columns.
Topics: Chromatography, Liquid; Chromatography, Reverse-Phase; Drug Contamination; Europe; Hydrogen-Ion Concentration; Pharmacopoeias as Topic; Prazosin; Time Factors | 2020 |
Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Catecholamines; Hemodynamics; Hormones; Humans; Pheochromocytoma; Prazosin; Retrospective Studies; Valsartan | 2022 |
Terazosin reduces steroidogenic factor 1 and upregulates heat shock protein 90 expression in LH-induced bovine ovarian theca cells.
Topics: Animals; Cattle; Cells, Cultured; Female; Heat-Shock Proteins; Humans; Prazosin; Steroid 17-alpha-Hydroxylase; Steroidogenic Factor 1; Theca Cells | 2021 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Denmark; Doxazosin; Female; Follow-Up Studies; Glycolysis; Humans; Male; Middle Aged; Parkinson Disease; Prazosin; Quinazolines; Registries; Risk Factors; Tamsulosin; United States | 2021 |
Transdermal iontophoresis delivery system for terazosin hydrochloride: an
Topics: Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; Animals; Antihypertensive Agents; Area Under Curve; Blood Pressure; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Guinea Pigs; Hypertension; Iontophoresis; Male; Prazosin; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Skin Absorption | 2021 |
Identification of novel therapeutic targets for contrast induced acute kidney injury (CI-AKI): alpha blockers as a therapeutic strategy for CI-AKI.
Topics: Acute Kidney Injury; Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Contrast Media; Endothelin-Converting Enzymes; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 14; Prazosin; Receptors, Adrenergic, alpha-1 | 2021 |
Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders.
Topics: Apoptosis; Caco-2 Cells; Cell Survival; Colitis; Cytokines; Deoxyglucose; Dextran Sulfate; Gastric Mucosa; Gastrointestinal Diseases; Glucose; Humans; Hydrogen Peroxide; Inflammation Mediators; Lactic Acid; Malondialdehyde; Models, Biological; Peroxidase; Phosphoglycerate Kinase; Prazosin; Pyroptosis; Stomach Ulcer; Superoxide Dismutase | 2021 |
Terazosin impairs athletic performance: Findings from an older geriatrician.
Topics: Geriatricians; Humans; Prazosin; Sports | 2022 |
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Humans; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Polymers; Prazosin; Serotonin; Synucleinopathies | 2022 |
Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; DNA-Binding Proteins; Humans; Mice; Motor Neurons; Phenotype; Phosphoglycerate Kinase; Prazosin; Zebrafish | 2022 |